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Abstract 
Methyl CpG binding protein 2 (MeCP2) was originally characterized as a 
transcriptional repressor that preferentially bound methylated DNA, however, recent data 
indicates MeCP2 is a multifunctional protein. MeCP2 is now shown to associate with 
expressed genes as well as repressed genes indicating its gene regulatory function is 
context dependent.  In addition, MeCP2 is involved in nuclear organization and proposed 
to regulate mRNA splicing.  Mutations in MECP2 are linked to the severe postnatal 
neurodevelopmental disorder Rett Syndrome (RTT).  To further understand MeCP2 and 
potential roles in RTT pathogenesis, we have employed a biochemical approach to 
identify the MeCP2 protein complexes present in the mammalian brain.  Here we show 
that MeCP2 exists in at least four biochemically distinct pools in the brain.  We 
characterize one novel brain-derived MeCP2 complex that contains the splicing factor 
Prpf3 and Sdccag1.  MeCP2 directly interacts with both Prpf3 and Sdccag1 in vitro 
independent of nucleic acids and certain RTT truncation disrupt the MeCP2-Prpf3-
Sdccag1 complex.  In addition, MeCP2 is localized to transcriptionally active Xenopus 
lampbrush chromosome loops and, both MeCP2 and Prpf3 associate in vivo with mRNAs 
of some genes thought to be regulated by MeCP2.  This data supports a regulatory role 
for MeCP2 in mRNA biogenesis and suggests an additional mechanism for RTT 
pathophysiology. 
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CHAPTER 1 
INTRODUCTION TO THE METHYL-CpG-BINDING PROTEIN MeCP2 
 
DNA METHYLATION 
 
A significant number of genes and a majority of non-protein coding DNA in a 
eukaryotic genome is silenced in any particular cell during the organism’s life (Elgin and 
Grewal, 2003).  This ‘silencing’ is associated with the formation of heterochromatic 
domains and is influenced by covalent modifications of chromatin components.  These 
epigenetic modifications are essential for normal development and can be re-established 
after each cell division to maintain stable cell identity (Bird, 2002; Jenuwein and Allis, 
2001; Kouzarides, 2002; Turner, 2000).  DNA methylation in the vertebrate genome is 
one such epigenetic mark generally associated with heterochromatin. 
Methylation of vertebrate genomes are characterized by the post-replication 
addition of a methyl group to the 5 carbon of cytosine (5mC) in CpG dinucleotides 
resulting in symmetrically methylated CpG dinucleotides on each strand.  The 
methylation reaction is carried out by members of the DNA methylatransferase (DNMT) 
family of proteins.  Currently DNMT1, DNMT3A and DNMT3B are the only recognized 
metazoan DNMTs (recently DNMT2 was identified as a tRNA methyltransferase (Goll et 
al., 2006).  Members of this family contain variable N-terminal regulatory regions and 
conserved C-terminal domain that catalyzes the transfer of a methyl-group from S-
adenosyl methionine (SAM) to the C5 position of cytosine.   
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The patterns of DNA methylation in a vertebrate genome are established through a 
sequence of developmental events (Razin and Shemer, 1995).  For examples, in mice, 
pre-implantation embryos undergo a global demethylation event followed by de novo 
remethylation carried out by DNMT3A and DNMT3B, which are critical in determining 
somatic DNA methylation patterns (Hsieh, 1999; Jaenisch et al., 1982; Okano et al., 
1998; Okano et al., 1999).  After these initial methylation patterns are established, they 
are maintained between cell generations by the maintenance methyltransferase DNMT1 
(Bestor et al., 1988; Leonhardt et al., 1992).  However, once established, DNA 
methylation patterns are not necessarily static and DNA demethylation can occur.  One 
regulator of active demethylation, Gadd45a, has recently been identified and shown to act 
by promoting DNA repair and ultimately demethylation of methylated DNA (Barreto et 
al., 2007; Rai et al., 2008; Schmitz et al., 2009).  Interestingly, Gadd45a knockout mice 
do not result in site specific or global hypermethylation (Engel et al., 2009), and the role 
of Gadd45a in DNA demethylation has been disputed (Jin et al., 2008).  Regardless, 
changes in developmental methylation patterns would suggest there are mechanisms 
controlling DNA methylation patterns in a specific manner. 
Studies suggest DNA methylation is important in establishing and maintaining 
heterochromatic structures for gene regulation (Eden et al., 2003; Gaudet et al., 2003).  
Transient transfection and in vitro transcription assays consistently demonstrate that the 
repression of transcription is dependent on DNA methylation (Levine et al., 1993; 
Murray and Grosveld, 1987).  However, experiments comparing transcription rates of 
methylated versus unmethylated stably integrated transgenes during Xenopus embryo 
development suggest the repressive nature of DNA methylation may be developmentally 
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controlled (Appendix A).  Two models have been proposed to explain the inhibitory 
effect of DNA methylation on transcription potential.  The first involves the direct 
interference of transcription factors from their binding sites by the presence of CpG 
methylation (Figure 1.1).  Research shows multiple proteins bind sequences containing 
CpG dinucleotides and some fail to bind when these sequences are methylated (Bell and 
Felsenfeld, 2000).  The other model involves proteins with a high affinity to methyl-CpG 
and facilitates the formation of a chromatin environment unfavorable for active 
transcription (Fahrner et al., 2002; Jones et al., 1998) by in turn recruiting repressive 
chromatin modifiers such as histone deacetylases (HDACs) and histone 
methyltransfereases (HMTs) to change the chromatin structure (Boyes and Bird, 1991; 
El-Osta et al., 2002; Fuks et al., 2003) (Figure 1.2).  This hypothesis is supported by the 
discovery of multiple methyl-CpG binding proteins.  
 
METHYL-CpG-BINDING PROTEINS 
 
Founding of the Methyl CpG Binding proteins (MBPs)  
In 1989, Adrian Bird’s lab was first to describe a nuclear activity that specifically 
interacted with CpG methylated DNA in-vitro, with no apparent requirement for a 
consensus binding sequence, and it was named MeCP (Meehan et al., 1990; Meehan et 
al., 1989).  This was achieved using double strand synthetic oligonucleotides which had 
been methylated in-vitro with bacterial methtransferases.  Competition of the MeCP 
activity binding to unmethylated DNA probes were detected only when the competitor 
DNA was methylated (Meehan et al., 1989).  This assay preferentially pulled down 
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protein from various tissues including: mouse brain, spleen, kidney, rat liver, and rabbit 
liver extracts.  In the various extracts, it appeared MeCP bound the methyl CpG DNA 
templates without sequence specificity.  However, further experimentation determined 
that MeCP was two distinct protein activities (named MeCP1 and MeCP2) with different 
requirements for methylated DNA (Meehan et al., 1992).  Meehan et al. identified that 
MeCP1 requires at least 12 symmetrically methylated CpGs while MeCP2 was able to 
bind a single methylated CpG pair.  Considering MeCP2 was reported to be 100 times 
more abundant in adult somatic nuclei than MeCP1 (Meehan et al., 1992), it was selected 
for further characterization and became the first MBP cloned and properly characterized.  
MeCP1 was finally identified and cloned in some years later, in 1999 (Ng et al., 1999).  
The initial hypothesis for MBP function was that they normally bind methylated DNA in 
a chromatin context, leading to long-term transcriptional silencing.  This idea was 
supported by results showing that digestion of rat brain nuclei with micrococcal nuclease 
released MeCP2, and that this chromatin “released” MeCP2 still retained the ability to 
bind a methylated DNA probe, but did not interact with unmethylated DNA (Meehan et 
al., 1992).  Furthermore, additional evidence was provided when transiently transfected 
constructs encoding a MeCP2 fused to the LacZ gene was expressed in mouse cell culture 
and similar localization to centromeric heterochromatin was observed (Lewis et al., 
1992).  Interestingly, the MeCP2-LacZ fusion was unable to localize to centromeric 
heterochromatin in methyltransferase deficient mouse cells, indicating MeCP2 requires a 
methylated chromatin substrate for proper distribution (Lewis et al., 1992).  This early 
MBP hypothesis prompted the isolation of MeCP2’s methyl CpG binding domain (MBD) 
by domain mapping, identifying amino acids 78 to 162 as the minimal region required to 
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bind methylated DNA (Nan et al., 1993) (Figure 1.3).  The identification of the first 
functional domain of MeCP2 allowed for bioinformatic analysis, which in turn led to 
identification of multiple relatives that share a related MBD (Cross et al., 1997; Hendrich 
and Bird, 1998).  
To date there are many proteins which have been identified as MBPs.  The known 
proteins which have affinity to methylated CpGs include the methyl CpG binding protein 
family (MBD1, MBD2, MBD3, MBD4, and MeCP2), and a structurally unrelated Kaiso 
family (Kaiso, ZBTB4, and ZBTB38).   
 
The Kaiso protein family  
Kaiso, ZBTB4, and ZBTB38 are members of Kaiso protein family which lack the 
conserved MBD characteristic of MBPs.  Instead, these proteins preferentially bind 
methylated DNA through zinc-finger domains (Filion et al., 2006; Prokhortchouk et al., 
2001).  Since the first Kaiso family member’s discovery, it has been attributed to multiple 
important functions.  Knockdown of Kaiso in X. laevis caused a premature activation of 
transcription in zygotes which resulted in apoptosis and developmental arrest (Ruzov et 
al., 2004).  This phenotype resembles knocking out specific DNA methyltransferases in X. 
laevis (Stancheva and Meehan, 2000), suggesting that Kaiso and DNA methylation-
mediated repression mechanisms are partly responsible for repression of transcription 
before the mid-blastula transition.  Interestingly, Kaiso knockout mice result in 
apparently normal development (Prokhortchouk et al., 2006).  Further functional studies 
in amphibian and mammal models suggest that the biological roles for Kaiso are not 
conserved (Prokhortchouk et al., 2006; Ruzov et al., 2004; Ruzov et al., 2009).  The two 
 5
other zinc-finger proteins, ZBTB4, and ZBTB38, are capable of binding methyl CpG 
DNA and have been shown to repress transcription in transient transfection assays (Filion 
et al., 2006).   
 
MBD1 
 MBD1 is the first named MBD protein identified in a bioinformatic search for 
MBD containing proteins (Hendrich and Bird, 1998).  MBD1 functions as a 
transcriptional repressor both in vivo and in vitro and can bind both methylated as well as 
unmethylated DNA depending on its splice isoform (Fujita et al., 2000; Ohki et al., 1999).  
MBD1-null mice have no obvious developmental defects, however, they do have minor 
neural defects and reduced genomic stability leading to increased transcription of some 
retrotransposon elements, supporting a role for MBD1 in repression of methylated DNA 
(Zhao et al., 2003).  MBD1 associates with chromatin modifiers such as Suv39h1 and 
HP1, and is involved in DNA methylation-mediated transcriptional repression (Fujita et 
al., 2003).  Another study showed that MBD1 associated with the H3K9 
methytransferase SETDB1 in HeLa cells (Sarraf and Stancheva, 2004).  During S phase, 
the MBD1-SETDB1 complex is recruited to chromatin by the chromatin assembly factor 
CAF1 to establish new repressive H3K9 methyl marks.  Furthermore, demethylation of 
specific promoters by 5-Azacitidine resulted in the disruption of the MBD1-SETDB1-
CAF1 complex and diminished H3K9 methylation levels, resulting in activation of 
normally repressed genes (Sarraf and Stancheva, 2004).  Interestingly, the interaction of 
MBD1 with other protein factors has been found to be negatively regulated by 
SUMOlation, providing a mechanism to control its repressive function (Lyst et al., 2006).   
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 MBD2           
    The second protein identified by MBD sequence homology in the study by 
Hendrich et al was aptly named MBD2.  Experiments from Adrian Bird’s group 
ultimately led to MBD2 as the protein responsible for MeCP1’s ability to preferentially 
bind methylated DNA (Ng et al., 1999).  It has been since determined that MBD2 is 
capable of binding methylated CpGs in vitro and in vivo and is responsible for 
transcriptional repression (Boeke et al., 2000; Ng et al., 1999).  It turned out MeCP1 
consisted of MBD2 in a complex with the Mi-2/NuRD chromatin remodeling complex 
(Zhang et al., 1999).  Developmentally, MBD2-null mice are apparently normal and 
remain viable and fertile; however female MBD2-null mice fail to nurture their pups 
properly (Hendrich et al., 2001).  A connection of MBD2 to this observed behavior 
remains unclear.   
 
MBD3 
Mammalian MBD3, although identified by its conserved MBD and is overall 
highly similar to MBD2, lacks the ability to preferentially bind methylated DNA in vivo 
or in vitro (Hendrich and Bird, 1998; Saito and Ishikawa, 2002).  Studies show 
mammalian MBD3 associates with the Mi-2/NuRD chromatin remodeling complex and 
its evolutionary conserved function as a transcriptional repressor remains intact (Saito 
and Ishikawa, 2002).  MBD2 and MBD3 interactions with Mi2/NuRD are mutually 
exclusive and creates two distinct complexes (Denslow and Wade, 2007; Feng and Zhang, 
2001).  Despite a similar amino acid sequence and mutually exclusive interactions with 
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the Mi-2/NuRD complex, MBD2 and MBD3 do not appear to perform redundant 
functions.  MBD3-null mice, in contrast to MBD2-null mice, are severely affected at day 
8.5 and subsequently die before birth and MBD3-null ES cells fail to shut down the 
expression of multiple undifferentiated ES cell markers leading to compromised ability to 
differentiate (Kaji et al., 2006; Kaji et al., 2007).  Interestingly, in contrast to mammals 
where both MBD2 and MBD3 interact with Mi-2/NuRD, the Xenopus laevis MBD3 
homolog retains the ability to bind methylated DNA and is the only MBD protein that has 
been shown to be a subunit of Mi-2/NuRD (Wade et al., 1999).   
 
MBD4  
 MBD4, much like the other MBD protein family members, has the potential to 
function as a transcriptional repressor – as demonstrated by a series of in vitro repression 
assays (Kondo et al., 2005).  However, it appears that MBD4 functions mainly as a 
thymine glycosylase, acting as a DNA repair protein that targets sites of cytosine 
deamination (Hendrich et al., 1999).  In methylated genomes, the GpG dinucleotide is 
under-represented.  This observation has been linked to spontaneous hydrolytic 
deamination of methylated cytosine which causes methylated CpG to TpG transitions, 
while non methylated CpG mutates to UpG (Bird, 1980).  Experimental evidence 
indicates MBD4 can excise and repair both types of mutated nucleotides (Hendrich et al., 
1999).  In line with this function, MBD4-null mice had a two to three times higher 
amount of mCpG to TpG mutation rate (Millar et al., 2002; Wong et al., 2002).  The 
relatively mild mutator phenotype and apparently healthy mice in these studies suggest 
that other thymine glycosylases might carry out similar functions.  Interestingly, one 
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recent study involving Gadd45 mediated active demethylation presented evidence that 
MBD4 may be involved in the process (Rai et al., 2008). 
 
MeCP2 
Since the time initial experiments in Adrian Bird’s lab identified MeCP2 as the 
founding member of methyl CpG binding proteins, multiple molecular roles have been 
proposed for the protein.  Studies suggest that MeCP2 is involved in transcriptional 
repression, transcriptional activation, nuclear organization, and splicing.  To further 
complicate the biology of MeCP2, new information about the MeCP2 gene itself has 
been reported.  A second isoform, labeled the e1 isoform, differs only in the first exon by 
providing an alternate amino terminal region when compared to the previously 
characterized e2 isoform of MeCP2 (Mnatzakanian et al., 2004) (Figure 1.3). The exact 
molecular context in which MeCP2 proteins functions in the proposed processes is not 
fully understood; however the data supporting the possible roles will be elaborated on 
further. 
 
Transcriptional regulation by MeCP2 
The MBD was the first functional domain isolated on MeCP2.  Deletion studies 
showed MeCP2 requires the MBD for its high binding affinity specifically for methylated 
DNA in vitro and for localization to the highly methylated pericentromeric 
heterochromatin in cell culture (Nan et al., 1993; Nan et al., 1996).  These data 
influenced the early driving hypothesis that MeCP2 binds methylated DNA in a 
chromatin context and function in long-term global silencing.  These studies were 
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conducted using murine MeCP2 in mouse cell cultures.  Further characterization of other 
MeCP2 homologs showed different preferences for methylated over unmethylated DNA.  
For example, the Xenopus MeCP2 homolog has a twenty fold higher affinity for 
methylated DNA when compared to unmethylated DNA (Fraga et al., 2003), where as 
the preference for human MeCP2 for methylated versus unmethylated DNA is 2 - 3 fold 
(Nikitina et al., 2007a).  Later experimentation involving in vitro binding site selection 
would reveal a requirement of human MeCP2 for an A/T nucleotide rich sequence 
adjacent to the target CpG methylation site, indicating a basis for sequence specificity in 
addition to methylation for MeCP2 binding (Klose et al., 2005).  
A biological role of MeCP2 was first illustrated by showing the protein represses 
transcription on methylated promoters in vitro and in the cell (Nan et al., 1997).  Using a 
β-actin transient transfection transcription assay, various MeCP2 domains were fused to 
the Gal 4 DNA binding domain and tested for the ability to repress transcription (Nan et 
al., 1997).  This method resulted in the identification of a specific fragment between 
amino acids 205 and 310 which is required for transcriptional silencing, defining the 
second domain of MeCP2 – the transcriptional repression domain (TRD) (Figure 1.3).  
Further experimentation has let to identification of other conserved domains in MeCP2, 
for example, a nuclear localization signal (Nan et al., 1996) and the WW domain binding 
region (WDR) thought to be involved in protein-protein interactions (Buschdorf and 
Stratling, 2004) (Figure 1.3).           
The ability of MeCP2 to silence transcription and its localization to densely 
methylated heterochromatin further supports the idea that MeCP2 functions as a general 
DNA methylation dependent transcriptional repressor.  One of the most compelling 
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models for MeCP2 mediated transcriptional repression is MeCP2 binding methylated 
DNA and subsequently the TRD of MeCP2 recruiting co-repressor complexes to create a 
chromatin environment unfavorable for transcription (Figure 1.2).  This model, 
suggesting MeCP2 as a functional link between DNA methylation and transcriptional 
repression, is supported by the observation that the TRD binds the co-repressor mSin3A 
which recruits histone deacetylase 1 and 2 (Jones et al., 1998; Nan et al., 1998; Wade et 
al., 1998).  The MeCP2-Sin3A-HDAC interaction is illustrated in multiple studies.  Jones 
et al. (1998) established that MeCP2 stably co-fractionates with the Sin3A-HDAC 
chromatin remodeling complex in Xenopus laevis, and that MeCP2 TRD mediated 
repression was relieved upon treatment with the histone deacetylase inhibitor TSA.  Nan 
et al. (1998) found immunoprecipitation of MeCP2 from rat brain nuclear extract 
contained Sin3A and histone deacetylase activity.  This idea is further supported by 
evidence that two MeCP2 target promoters, the brain-derived neurotrophic factor (Bdnf) 
and xHairy2a, are also bound by Sin3A (Chen et al., 2003; Klose and Bird, 2003; 
Martinowich et al., 2003; Stancheva et al., 2003).    These data indicate MeCP2 is 
targeted to methylated promoter DNA and result in strong transcriptional repression via 
post-translational modifications of histone tails (Jones et al., 1998; Nan et al., 1998).  
However, this model is not universally applicable to MeCP2 function due to the 
observation that, depending on the promoter in question, histone deacetylase independent 
transcriptional repression by the protein can occur (Yu et al., 2000).  Furthermore, a lack 
of global changes in histone tail modifications in MeCP2-null mice also argues against 
this as the sole functional model (Urdinguio et al., 2007).   
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Additional co-repressors, such as NCoR and c-Ski, have also been identified as 
interacting directly with MeCP2 (Kokura et al., 2001).  Furthermore, Harikrishnan et al. 
(2005) demonstrated that that SWI/SNF chromatin-remodeling complex Brahma 
associates with MeCP2 in cell culture and is functionally linked with repression.  The 
stability of co-repressor interactions with MeCP2 is controversial due to data from one 
study that shows the native protein is an elongated monomer that does not associate with 
anything in rat brain nuclear extracts or Xenopus oocyte extracts (Klose and Bird, 2004).  
Oddly, this study is in disagreement with that same lab’s previous published and 
unretracted work showing MeCP2 stably interacts with Sin3A-HDAC in rat brain nuclear 
extracts (Nan et al., 1998). Thus, the biochemical makeup of endogenous MeCP2 
complexes is still not clear. 
 Although experimental evidence suggests MeCP2 might serve as a global 
transcriptional silencer (Jones et al., 1998; Nan et al., 1998), transcriptional profiling 
studies of MeCP2-null mice brains exhibit only subtle changes in gene expression.  Of 
the few genes upregulated in the MeCP2-null mouse model, the largest change in 
expression was attributed to the Irak1 gene – showing a twofold increase in expression 
(Tudor et al., 2002).  These findings were later confirmed in a microarray hybridization 
study using RNA from the cerebellum of MeCP2 mutant mice (Jordan et al., 2007).  
Similarly, cultured human cell-lines with naturally occurring dysfunctional MeCP2 
mutations showed only 49 upregulated and 21 downregulated targets by comparing 
global expression levels of potential MeCP2 target genes (Traynor et al., 2002).  Taken 
together, these data may suggest MeCP2 is not strictly involved in global transcriptional 
repression.  In fact, recent work raised further questions about how MeCP2 functions at 
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the cellular level.  Yasui et al. (2007) preformed a global epigenomic binding analysis of 
MeCP2 using a ChIP- (microarray) chip approach.  Two novel insights into possible 
functions of MeCP2 were revealed by this work.  The first is MeCP2 is often associated 
with actively transcribed genes, and not always with transcriptionally repressed genes.  
Secondly, the majority of MeCP2 binding sites are intergenic within the genome.  Using 
the human SH-SY5Y neuroblastoma cell line as a source of MeCP2 bound chromatin for 
immunoprecipitations, the ChIP-chip analysis first focused on a 26.3Mb chromosomal 
loci containing known MeCP2 target genes.  From this, a majority of MeCP2 (59%) was 
found to bind mostly non-methylated sites along intergenic spaces (Yasui et al., 2007).  
Furthermore, 63% of MeCP2-bound promoters were found to be actively transcribed 
(Yasui et al., 2007).  Being contradictory to the traditional model of MeCP2 binding 
densely methylated promoters to repress transcription, the group compared genome-wide 
promoter methylation to MeCP2 binding by methylated DNA immunoprecipitation 
(MeDIP).  The comparison revealed that only 2% of promoters with high levels of 
methylation were bound by MeCP2 (Yasui et al., 2007).  Importantly, the results 
obtained from the cell culture based experiments were reinforced by an in vivo model, 
further suggesting MeCP2 is associated with actively transcribed genes.  Experiments 
profiling transcript expression levels of hypothalamus isolated from MeCP2 
overexpressing mice or MeCP2-null mice and comparing them to wild type mice show 
that MeCP2 is not strictly associated with gene repression, but activate transcription on 
the majority of its targets (Chahrour et al., 2008).  Although indirect effects were 
considered, the presence of MeCP2 at some of the activated gene promoters was 
validated by ChIP and shown to be associated with the transcriptional activator CREB-1 
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(Chahrour et al., 2008).  These surprising results illustrate that the complete biological 
function of MeCP2 is not fully understood.  
 Aside from the global aspects of transcriptional regulation by MeCP2, its ability 
to regulate specific loci has been investigated.  One extensively characterized target of 
MeCP2 is the brain-derived neurotrophic factor (BDNF) promoter III.  Initial studies in 
mouse and rat neurons show MeCP2 dissociates from the BDNF promoter upon a 
calcium influx induced membrane depolarization, allowing transcription of BDNF to 
occur (Chen et al., 2003; Martinowich et al., 2003).  ChIP experiments show the 
repression of BDNF is mediated though MeCP2 recruitment of the Sin3A-HDAC co-
repressor complex, and depolarization disrupts chromatin remodeling activities required 
for repression of BDNF (Martinowich et al., 2003).  Furthermore, Western blot analysis 
of neuronal lysates revealed MeCP2 is phosphorylated by membrane depolarization, 
leading to dissociation from the BDNF promoter binding site (Chen et al., 2003).  Later 
work revealed multiple phosphorylation sites on neuronally derived MeCP2 (Tao et al., 
2009; Zhou et al., 2006).  MeCP2 can be phosphorylated at the serine 421 residue by a 
CaMKII kinase.  This post-translational modification is responsible for MeCP2 
dissociation and transcriptional activity of the BDNF promoter (Zhou et al., 2006).  
Interestingly, phosphorylation at another residue, serine 80, can also modulate chromatin 
binding of MeCP2.  In contrast to serine 421, phosphorylation of serine 80 is important 
for the association of MeCP2 with chromatin, and membrane depolarization of neurons 
by calcium influx induces dephosphorylation of this residue (Tao et al., 2009).          
         
 
 14
Other functions of MeCP2 
 Affinity for DNA methylation and histone deacetylase dependent chromatin 
remodeling has been the dominant topic in the history of studying MeCP2.  However, 
research over the years has expanded the proteins functional role beyond that of 
transcriptional regulation.  The initial implication that MeCP2 may have a role in global 
chromatin architecture came from early research showing chicken MeCP2 (ARBP) has a 
high affinity for matrix attachment regions (MARs) (Weitzel et al., 1997).  Later, in vitro 
studies demonstrate binding of MeCP2 to chromatin templates and directly inducing 
chromatin compaction (Georgel et al., 2003; Nikitina et al., 2007a; Nikitina et al., 2007b).  
Although there is an obvious preference for MeCP2 binding methylated linker DNA of 
chromatin templates (Ishibashi et al., 2008; Nikitina et al., 2007a), it is clear that MeCP2 
is able interact with unmethylated chromatin templates.  Using nucleosome arrays and 
electron microscopy, MeCP2 has been visualized binding chromatin fibers, in the 
absence of DNA methylation, ATP, or other chromatin remodelers, and directly 
compacting them into folded structures (Georgel et al., 2003; Nikitina et al., 2007b).    
During myogenic differentiation of tissue culture cells, MeCP2 can induce large scale 
rearrangements of heterochromatin (Brero et al., 2005).  Ectopic expression of 
fluorescently tagged MeCP2 was shown to mimic the effect, causing a dose-dependent 
clustering of chromocenters in the absence of differentiation (Brero et al., 2005).  
Moreover, experiments utilizing ChIP coupled with chromosome conformation capture 
indicate the Dlx5-Dlx6 imprinted gene cluster requires MeCP2 to form chromatin loops 
on the imprinted allele (Horike et al., 2005).  Interestingly, in the absence of MeCP2, one 
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of the few genes upregulated in knock-out mice is SATB1, a protein known to bind 
specifically to MARs and mediate the formation of chromatin loops (Jordan et al., 2007).     
 In addition to transcriptional regulation and nuclear architecture, MeCP2 function 
has also been linked to mRNA splicing (Jeffery and Nakielny, 2004; Young et al., 2005).  
One in vitro study indicates that MeCP2, via the interdomain region between the MBD 
and TRD, can bind RNA directly with high affinity (Jeffery and Nakielny, 2004) (Figure 
1.3).  Furthermore, the binding of RNA is mutually exclusive from MeCP2 interacting 
with methylated DNA, and can do so independently of the MBD (Jeffery and Nakielny, 
2004).  In another study using HeLa cell extracts for coimmunoprecipitation experiments, 
epitope tagged MeCP2 was found to interact with the messenger ribonucleoprotein 
particle component YB-1 (Young et al., 2005).  The YB-1 protein is a multifunctional 
protein and considered to be the main mRNA packing protein.  The MeCP2-YB-1 
interaction is dependent on the presence of RNA, as MeCP2 coimmunoprecipitation 
treated with RNase failed to pull down YB-1 along with MeCP2 (Young et al., 2005).  It 
is unknown if the MeCP2-YB-1 complex is a protein-protein interaction stabilized by 
RNA or if it is a result of the two proteins interacting with the same mRNA transcript.  
Additionally, MeCP2 overexpression in cell culture can affect the alternative splicing of 
transiently transfected reporter minigenes (Young et al., 2005).  This information, along 
with a microarray splicing analysis of cerebral cortex mRNA isolated from MeCP2-null 
mice showing multiple aberrantly spliced genes, imply that MeCP2 may have a role as a 
splice site regulator (Young et al., 2005).              
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MeCP2 and Rett syndrome   
Mutations in MeCP2 cause the majority (96%) of cases diagnosed as the severe 
neurodevelopmental disorder Rett syndrome (RTT) (Amir et al., 1999).  MeCP2 is an X-
linked gene and RTT occurs in approximately one out of every 10,000 females (Percy, 
2002), however non-lethal mutations of the gene in males have been reported (Ravn et al., 
2003).  Females with RTT develop normally after birth up to 6 to 18 months of age, after 
which they show regression, with deceleration of head growth, loss of speech and 
acquired motor skills, as well as severe mental retardation (Hagberg et al., 1983).  Of the 
2000 reported mutations in MeCP2 causing RTT, there are eight common mutational 
hotspots found in the MBD and TRD that result in loss of a functional protein (Bienvenu 
and Chelly, 2006).  Taking into account both MeCP2 e1 and e2, mutations predicted to 
affect either isoform alone are rare yet known to cause RTT (Mnatzakanian et al., 2004).   
Although both isoforms are highly expressed in the brain and MeCP2 e1 is more 
prevalent (Kriaucionis and Bird, 2004), and there is differential distribution of the two 
between the dorsal thalamus and hypothalamus in developing postnatal mouse brains 
(Dragich et al., 2007).  The functional significance of this is unknown, but suggests there 
may be important difference between the two isoforms.   
Multiple mouse models of RTT have been developed using Cre-lox technology, 
each having different mutation type and phenotype severity.  MeCP2 knock out mice 
show a period of normal development followed by progressive neurological dysfunction 
leading to death by 10 weeks (Chen et al., 2001; Guy et al., 2001).    MeCP2 mutations 
restricted to neuronal lineages result in a phenotype indistinguishable from that of 
MeCP2 knockout mice, indicating MeCP2 dysfunction in neurons is sufficient to cause 
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disease (Chen et al., 2001; Guy et al., 2001).  Inactivation of Mecp2 in post-mitotic 
neurons cause delayed onset of phenotypes similar to those of MeCP2-null mice, 
demonstrating that MeCP2 plays an essential role in post-mitotic neuronal function (Chen 
et al., 2001).  Conversely, expression of MeCP2 in post-mitotic neurons of MeCP2 
knockout mice show normal neurological function, indicating that MeCP2 plays no 
essential roles in early brain development and deficiency in non-neuronal tissues does not 
significantly influence disease progression (Luikenhuis et al., 2004).  However, this idea 
is being challenged by a recent study indicating the lack of MeCP2 specifically in glial 
cells contributes to RTT phenotypic neurons by an unknown secreted glial factor (Ballas 
et al., 2009).  Further functional studies found that mice carrying a duplicate copy of the 
gene and therefore overexpressing MeCP2 result in a severe postnatal, neural phenotype 
(Collins et al., 2004).  Taken all together, it appears MeCP2 must be tightly regulated in 
the brain for normal function.      
MeCP2 has been implicated in gene regulation, splicing, and genome organization, 
yet how MeCP2 functions in the brain and the lack of a functional MeCP2 protein leads 
to disease is unknown.  There is no solid evidence linking a target of MeCP2 to RTT, 
however, BDNF overexpression in MeCP2 knockout mice do show an extended life span 
(Chang et al., 2006).  Notably, MeCP2-null mice show aberrant RNA-splicing patterns; 
indicating lack of MeCP2 may not only affect transcriptional control (Young et al., 2005).    
The complexity of RTT would suggest MeCP2 dysfunction is a combination of affects 
recognized as disease.  Importantly, studies suggest that mice deficient in MeCP2 do not 
suffer irreversible damage, and that restoration of a functional MeCP2 can lead to a 
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reduction of neurological symptoms (Giacometti et al., 2007; Guy et al., 2007; 
Luikenhuis et al., 2004).        
  There is a need to reveal the normal molecular mechanisms of MeCP2 function 
in the brain.  Identification of interacting protein partners has proven many times over as 
a way to elucidate the function of proteins.  Characterization of novel brain-specific 
MeCP2 protein complexes will yield insight into its molecular function and dysfunction 
in RTT.  Here we biochemically characterized MeCP2 in adult rat brain and show that it 
exists in multiple biochemically distinct pools.  One brain-derived MeCP2-complex 
shows a direct association with the pre-mRNA processing factor 3 (Prpf3), a known small 
nuclear ribonucleoprotein associated factor, and the serologically defined colon cancer 
antigen 1 (Sdccag1), a mediator of nuclear export.  Furthermore, we find that MeCP2 and Prpf3 
associates with mRNA in-vivo, further supporting the regulatory role of MeCP2 in 
mRNA splicing and providing another potential mechanism of pathogenesis in RTT. 
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FIGURES 
 
 
 
 
 
 
Figure 1.1:  Schematic of model for DNA methylation mediated inhibition by direct 
interference.  A)  When unmethylated CpGs (open circles) are present at a target 
promoter, transcription factors are able to bind and initiate transcription.  B)  When a 
promoter contains CpGs that are methylated (closed circles), transcription factors are 
unable to bind, thus inhibiting transcription.    
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Figure 1.2:  Schematic of model for DNA methylation mediated repression by 
recruitment of methyl-binding proteins (MBPs) and co-repressors.  A)  When 
unmethylated CpGs (open circles) are present at a target promoter, transcription factors 
are able to bind and initiate transcription.  B)  Promoter containing CpGs that are 
methylated (closed circles) allow for MBP binding and subsequent recruitment of 
repressive chromatin modifiers, thus inhibiting transcription. 
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Figure 1.3:  Schematic of MeCP2 domains.  A)  The commonly studies MeCP2 e2 
isoform and its domains: MBD – methyl-binding domain; TRD – transcriptional 
repression domain; NLS – nuclear localization sequence; WDR - WW domain binding 
region.  B) MeCP2 e1 isoform is identical to e2, except for an extra 5’ exon providing an 
additional 21 amino acids (*) at the amino termini.      
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CHAPTER 2*  
 
A BRAIN-DERIVED MeCP2 COMPLEX 
SUPPORTS A ROLE FOR MeCP2 IN RNA PROCESSING 
 
* Some of the data and writing is adapted from: 
  
Steven W. Long, Jenny Y. Y. Ooi, Peter M. Yau , and Peter L. Jones  A Brain-Derived MeCP2 Complex Supports a Role for 
MeCP2 in RNA Processing. NAR, 2010 
 
 
INTRODUCTION 
 
MeCP2 was originally identified by its ability to preferentially bind double 
stranded DNA containing symmetrically methylated CpG dinucleotides and is the 
founding member of the methyl-CpG-binding domain (MBD) family of proteins 
(Hendrich and Bird, 1998; Meehan et al., 1992).  The first biological role for MeCP2 was 
illustrated by showing the protein interacts with methylated DNA in vivo and can repress 
transcription by association with a transcriptional co-repressor complex containing Sin3A 
and histone deacetylase (Jones et al., 1998; Nan et al., 1997; Nan et al., 1998).  In 1999 a 
genetic analysis identified mutations in MECP2 as causal of Rett Syndrome (RTT), the 
first direct link between an epigenetic regulator and a human disease (Amir et al., 1999).  
RTT is a severe postnatal neurodevelopmental disorder and one of the most common 
causes of mental retardation in females (Chahrour and Zoghbi, 2007).  First described in 
1966 by Andreas Rett (Rett, 1966), RTT is characterized by a period of apparently 
normal development from birth to 6-18 months followed by a regression of obtained 
language and motor skills (Chahrour and Zoghbi, 2007).  RTT patients usually exhibit a 
deceleration of head growth, respiratory dysfunction, scoliosis, cognitive impairment, 
seizures, and social withdraw (Hagberg et al., 1983; Rett, 1966).  In addition to RTT, 
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numerous MECP2 mutations have now been linked to a variety of additional disorders, 
including autism, Angelman syndrome, learning disabilities, and mental retardation 
syndromes (Carney et al., 2003; Chahrour and Zoghbi, 2007; Christodoulou and Weaving, 
2003; Lam et al., 2000; Watson et al., 2001; Ylisaukko-Oja et al., 2005; Zoghbi, 2005).   
Along with the discovery of MeCP2’s association to human diseases, MeCP2 has 
also been reported to associate with myriad protein partners including Sin3A (Jones et al., 
1998; Nan et al., 1998), c-REST and Suv39h1 (Lunyak et al., 2002), c-Ski and N-CoR 
(Kokura et al., 2001), Brm (Harikrishnan et al., 2005), and HP1 (Agarwal et al., 2007), 
all supporting a model of MeCP2 interacting with or being a stable component of co-
repressor complexes, resulting in targeted transcriptional repression of methylated DNA 
through modification of the chromatin state.  Despite this early focus on gene specific 
repression, more recent work has expanded MePC2’s gene regulatory role beyond 
transcriptional repression; MeCP2 is implicated in transcriptional activation, genome-
wide transcriptional silencing, mediating chromatin and nuclear architecture, and 
regulating pre-mRNA splicing as well (Chadwick and Wade, 2007; Chahrour et al., 
2008; Skene et al.; Yasui et al., 2007; Young et al., 2005).  Genome-wide chromatin 
immunoprecipitation (ChIP) assays from cultured neuronal cell lines indicate MeCP2 
binding resembles that of RNA polymerase II and MeCP2 recruits CREB to activate 
specific genes (Chahrour et al., 2008; Yasui et al., 2007).  Overexpressed MeCP2 in cell 
culture leads to clustering of MeCP2-associated chromatin (Brero et al., 2005), while in 
vitro, MeCP2 does not require any additional proteins to condense chromatin into higher 
order structures, illustrating a co-repressor independent function for MeCP2 in affecting 
chromatin structure (Georgel et al., 2003; Nikitina et al., 2007).  Recently, a genome-
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wide ChIP-bisulfite sequencing analysis found that in purified mouse brain neurons 
MeCP2 bound to methylated DNA sequences with high selectivity and maintained 
depressed global histone acetylation levels suggesting that in neurons MeCP2’s main 
DNA associated function was as a genome-wide repressor of methylated DNA sequences 
(Skene et al.).  In addition to binding methylated DNA, MeCP2 also binds multiple RNA 
species, including mRNA, and binding to RNA and methylated DNA are distinct, 
mutually exclusive interactions (Jeffery and Nakielny, 2004).  Combined with the RNA-
dependent association of MeCP2 with Y box-binding protein1 (YB-1), a component of 
messenger ribonucleoprotein (RNP) particles, to regulate splicing of reporter minigenes, 
MeCP2 is implicated as being directly involved in mRNA splicing (Young et al., 2005).  
Overall, the biology of MeCP2 suggests a truly multifunctional protein (Hite et al., 2009) 
with cell type specific functions and associations. The exact molecular process(es) 
disrupted in neurons by the pathogenic mutations in MECP2 remains unclear. 
Genetic studies in mice suggest that functional MeCP2 in neurons is essential for 
normal synapse formation and neuronal function during postnatal development and re-
expression of MeCP2 in differentiated neurons alone rescues a RTT mouse model (Chen 
et al., 2001; Guy et al., 2001; Kishi and Macklis, 2004; Luikenhuis et al., 2004; 
Shahbazian et al., 2002b; Zoghbi, 2003).  However, this idea is being challenged by a 
recent study indicating the lack of MeCP2 specifically in glial cells contributes to RTT 
phenotypic neurons by an unknown secreted glial factor (Ballas et al., 2009).  This 
discrepancy illustrates the need for more unbiased approaches in determining the 
molecular role of MeCP2 in RTT; thus, intact mammalian brain tissue would be the ideal 
source to study endogenous MeCP2 protein complexes.  Here we use the power of 
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biochemistry to characterize MeCP2 in the mammalian brain and show that native 
MeCP2 protein purified from adult rat brain exists in multiple biochemically distinct 
pools, consistent with MeCP2 working as a multi-functional protein.  We further 
characterize one brain-derived MeCP2-complex that contains Prpf3, a known 
spliceosome-associated protein (Wang et al., 1997), as well as the Sdccag1 (Scanlan et 
al., 1998), a mediator of nuclear export (Bi et al., 2005).  MeCP2 shows specific, direct 
interactions with Prpf3 and Sdccag1 and these interactions are disrupted by certain RTT 
mutations.  In addition, we show that MeCP2 and Prpf3 co-associate in vivo with mRNAs 
from genes activated by MeCP2, further supporting the previously identified regulatory 
role of MeCP2 in mRNA biogenesis (Young et al., 2005) and providing another potential 
mechanism disrupted during pathogenesis of RTT. 
 
RESULTS 
 
MeCP2 exists in at least four distinct protein pools in rat brain nuclei 
  A large-scale biochemical purification of endogenous MeCP2 protein from rat 
brain nuclear extract was performed to characterize the native MeCP2 in the mammalian 
brain.  Whole rat brains were homogenized under non-denaturing conditions, the intact 
nuclei were purified by centrifugation through a sucrose cushion, and nuclear proteins 
were extracted under mild ionic conditions.  Proteins were initially fractionated by strong 
anion exchange (MonoQ) column chromatography (Figure 2.1A) with the MeCP2 protein 
being tracked by western blotting with multiple MeCP2-specific antibodies (Figures 2.2), 
all providing virtually identical profiles.   
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The majority of soluble MeCP2 protein did not bind the MonoQ resin (Figure 
2.1A, lane QF).  To determine possibility of proteins associating with MeCP2 in the 
MonoQ flow through (QF MeCP2), complexity was reduced by multiple steps of liquid 
chromatography fractionation consisting of MonoS strong cation exchange 
chromatography, heparin affinity chromatography, and gel filtration through Superose6 
(Figure 2.3).  After gel filtration, western blotting and silver stain analysis indicates 
MeCP2, confirmed by spectrometry (Figure 2.4), does not co-fractionate with any other 
polypeptides (Figure 2.5), thus confirming a previous report (Klose and Bird, 2004).                 
A significant fraction (10%) of the brain-derived MeCP2 consistently interacted 
with the anion exchange resin, consistently eluting in two distinct peaks along a linear 
salt gradient, indicating multiple biochemically distinct pools of MeCP2 (Figure 2.1A).  
The MonoQ bound (QB)  MeCP2 elution profile showed an initial broad peak (QB1/2) 
concentrated at 230mM NaCl and tailing to 370mM, suggesting multiple MeCP2 forms, 
with a minor yet distinct peak (QB3) centered at 450mM NaCl (Figure 2.1A).  Since 
MeCP2 is a DNA binding protein and also known to interact with RNA, the potential of 
nucleic acids mediating the anionic association of MeCP2 with the cationic resin was 
addressed.  The QB fractions were treated with benzonase nuclease to remove all DNA 
and RNA and the MonoQ chromatography was repeated.  In each case, all of the 
nuclease-treated QB MeCP2 again bound the MonoQ resin and was released by step 
elution, indicating the interaction was both RNA and DNA independent (Figure 2.6A).  
Futhermore, MeCP2 is known to be phosphorylated (Tao et al., 2009; Zhou et al., 2006).  
To determine if phosphorylation of MeCP2 is responsible for the interaction with the 
MonoQ resin, QB fractions were treated with calf intestinal phosphotase (CIP) and the 
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MonoQ chromatography was repeated.  All of the CIP-treated QB MeCP2 again bound 
the MonoQ resin and was released by step elution, indicating the interaction was not due 
to phosphorylation of MeCP2 (Figure 2.6B).    Finally, the presence of MeCP2 in the 
MonoQ elution peak (QB1/2 and QB3) was confirmed by mass spectrometry (Figure 2.4).   
The more abundant MonoQ bound pool of MeCP2 (QB1/2) was characterized for 
complexity and content (Figure 2.1A).  The QB1/2 peak fractions were pooled and 
fractionated over the MonoS strong cation exchange resin, resolving into two peaks of 
MeCP2 protein (Figure 2.1B), the first eluting at 400mM NaCl (QB1) and the second 
eluting at 550mM NaCl (QB2), therefore indicating at least three biochemically distinct 
pools of MeCP2 exist in the initial QB fraction and four MeCP2 pools exist overall in rat 
brain nuclear extract (QF and QB1-3).   
 
Brain-derived MeCP2 exists in a putative RNA processing complex 
In order to identify potential MeCP2-interacting proteins, the more abundant 
MonoS bound pool of MeCP2 (QB2) was purified further by fractionation using heparin 
affinity chromatography and gel filtration through Superose6 (Figure 2.7).  Western 
blotting and silver stain analysis of the final fractionation showed MeCP2 peaking with 
the apparent molecular weight of 600-700kDa and precisely co-purifying with six 
additional polypeptides (Figures 2.8 and 2.9).  Therefore, all six MeCP2 co-purifying 
polypeptides were identified by mass spectrometry with significant coverage (Figure 
2.10) as:  Prpf3, Sdccag1, ATP-binding cassette 50, and 3 components of a translation 
initiation complex (Eif2 subunits 1, 2, and 3). Since a commercial antibody was available 
against Prpf3, western blot analysis of the size exclusion chromatography fractions were 
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carried out and show MeCP2 and Prpf3 precisely co-fractionate (Figure 2.8, bottom) 
confirming the silver-stain analysis (Figure 2.8 and 2.9). 
With Prpf3 identified as a putative MeCP2-interacting protein, the MeCP2 
fractionation scheme (Figure 2.7) was analyzed for Prpf3 by western blotting to 
determine if Prpf3 was present in all MeCP2 pools or specific to QB2 and similarly to 
determine if all Prpf3 in brain extracts associated with MeCP2.  Not surprisingly, only a 
fraction of Prpf3 in brain extracts co-fractionated with MeCP2 when assaying the MonoQ 
separation profile (Figure 2.11A), however, all of the detectable Prpf3 overlapping with 
MeCP2 specifically co-fractionated with the QB2 pool of MeCP2 from the MonoS 
fractionation and not with the QB1 MeCP2 pool (Figure 2.11B).  Thus, Prpf3 
distinguished QB2 from other MeCP2 protein pools.  Because Prpf3 is a known 
component of the spliceosome (Wang et al., 1997) and MeCP2 has been shown to 
interact with another spliceosome-associated protein, YB-1 (Young et al., 2005), the QB2 
fractionation was screened for YB-1.  However, YB-1 was not found by western blotting 
and YB-1 was absent from the mass spectrometry analysis, indicating YB-1 did not co-
purify with QB2 MeCP2 under these conditions (data not shown). 
To confirm that native MeCP2 and Prpf3 were in a complex in vivo, co-IP 
experiments were performed (Figure 2.12).  In brain extracts, as determined by the 
biochemical fractionations described above, the vast majority of MeCP2 is not associated 
with Prpf3 and likewise, the majority of Prpf3 in brain is not associated with MeCP2 
making it difficult to visualize any interaction by co-IP directly from crude nuclear 
extracts.  Thus, two approaches were used; co-IPs from fractionated brain nuclear extract 
(Figure 2.12A) and co-IPs from crude extracts using tissue culture cells overexpressing 
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an epitope tagged version of MeCP2 (Figure 2.12B).  Rat brain nuclear extract was 
prepared and fractionated over monoQ and monoS resins as described above for QB2.  
The peak MeCP2 and Prpf3 containing fractions were made to 100 mM NaCl in buffer A 
and used for co-IP experiments assayed by western blotting.  Using the anti-MeCP2 
antibody to IP, Prpf3 was specifically co-IP’ed from these fractions and the interaction 
between MeCP2 and Prpf3 was not dependent on nucleic acids (Figure 2.12A, lane 3 and 
4).  Alternatively, to show co-IP interaction between MeCP2 and Prpf3 from crude cell 
extracts, the murine hippocampal HT-22 cell line was used to generate a pool of cells 
stably expressing a HA-tagged version of human MeCP2.  Immunofluorescence showed 
that HA-MeCP2 in these cell lines predominantly concentrated to DAPI-rich 
heterochromatic foci as expected for endogenous MeCP2 (Figure 2.13).  Anti-HA 
antibodies were then used to specifically co-IP HA-MeCP2 and MeCP2-associated 
proteins from these cell lines.  Western blotting showed that HA-MeCP2 specifically co-
IP’ed a fraction of the endogenous mouse Prpf3 (Figure 2.12B, lane 3), indicating that 
Prpf3 and MeCP2 exist in a stable complex within these neuronal cells, and the 
interaction between MeCP2 and Prpf3 was not dependent on nucleic acids (Figure 2.12B, 
lane 4).  We conclude that MeCP2 and Prpf3 exist in a native complex in vivo. 
 
MeCP2 interacts directly with Prpf3 and Sdccag1 and independent of nucleic acids 
To investigate which of the co-purifying candidate proteins directly interacted 
with MeCP2, the cDNAs for each identified protein was cloned and the recombinant 
proteins were tested for their ability to interact with MeCP2 in vitro (Figure 2.14).  GST 
pull-down assays using a GST-MeCP2 fusion protein showed that rat Prpf3 specifically 
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interacted with full-length rat MeCP2, but not GST alone (Figure 2.14A, left panel), and 
reciprocally, rat GST-Prpf3 interacted with rat MeCP2 (Figure 2.14B).  Furthermore, 
treatment of the GST-MeCP2/Prpf3 reaction with benzonase nuclease showed the 
interaction was not dependent on nucleic acids (Figure 2.14A, B).  Similarly, rat Sdccag1 
specifically interacted with rat GST-MeCP2 in a nucleic acid independent manner 
(Figure 2.14A, middle panel).  Interestingly, neither rat GST-MeCP2 nor rat GST-Prpf3 
interacted with any of the other four identified polypeptides supporting the specificity of 
the observed interactions of MeCP2, Prpf3 and Sdccag1 (Figure 2.14A, right panel and 
data not shown).   
 
Prpf3 interacts with the MeCP2 MBD and transcriptional repression domain (TRD) 
and Sdccag1 interacts with the MeCP2 carboxyl terminal region   
 
The regions of MeCP2 that mediate the direct interaction with Prpf3 were mapped 
by GST pull-down.  A series of bacterially generated human GST-MeCP2 deletion 
mutants were tested for their ability to interact with in vitro synthesized human Prpf3 
(Figures 2.15A and 2.16).  Prpf3 retained the ability to interact with MeCP2 N-terminal 
deletions up through amino acid residue 195 as well as a C-terminal deletion lacking 
amino acid residues 309 – 486.  However, Prpf3 did not interact with a MeCP2 deletion 
lacking amino acid residues 1 – 308, indicating that the TRD region is required for 
interaction (Figure 2.15A, upper panel and 2.16).  Therefore, a fragment of MeCP2 that 
contains only amino acid residues 207-308, corresponding to the TRD domain, was tested 
and found to interact with Prpf3 with similar apparent affinity as full length MeCP2.  
Similarly, rat Sdccag1 was synthesized in vitro and subjected to the same series of GST-
MeCP2 deletions as Prpf3 (Figure 2.15A, lower panel and 2.16).  Sdccag1 was able to 
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interact with all of the N-terminal MeCP2 deletion proteins tested, but failed to interact 
with a MeCP2 deletion lacking the region C-terminal to the TRD.  Thus, MeCP2’s 
interaction domain with Sdccag1 resides between amino acid residues 309–486, adjacent 
with the Prpf3 interaction domain.   
Considering most known RTT mutations reside in MECP2, it is likely that some 
of these mutations would also disrupt the interactions of Prpf3 and/or Sdccag1 with 
MeCP2.  A series of bacterially generated human GST-MeCP2 RTT nonsense mutants 
were produced and tested for their ability to interact with in vitro synthesized human 
Prpf3 and rat Sdccag1 (Figure 2.15B and 2.16).  The series of RTT mutations truncate 
MeCP2 ranging from amino acids 49 to 204.   All of these RTT nonsense mutants lack 
the C-terminal region of MeCP2 and therefore disrupted its interaction with Sdccag1 as 
expected (Fig 15B, bottom panel and 16).  The Prpf3 interaction was disrupted by RTT 
truncations at amino acids S49X, S68X and W104X as well.  However, the Prpf3 
interaction with MeCP2 was maintained with the RTT truncations Y141X, R168X, and 
S204X (Fig 15B, top panel and 16).  This indicates there are two MeCP2 regions capable 
of interacting with Prpf3 flanking the inter-domain region between the MBD and TRD of 
MeCP2.  Interestingly, this same inter-domain region of MeCP2 has been previously 
characterized as the RG domain and is required for MeCP2’s RNA binding activity 
(Jeffery and Nakielny, 2004).  Several common RTT point mutants, as well as additional 
RTT truncations, were similarly tested and found to have no impact on MeCP2’s ability 
to interact with Prpf3 (Figure 2.15C).   We conclude that MeCP2 contains two domains 
sufficient for interaction with Prpf3, one in the MBD between amino acids 104 and 141, 
and the second in the TRD between amino acids 207 and 294 and one domain for 
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MeCP2’s interaction with Sdccag1, residing between amino acids 311 and 486 (Figure 
2.15D).  Therefore, any RTT mutation truncating MeCP2 at or before amino acid residue 
104 will abolish the Prpf3 interaction, while any RTT truncation at or before amino acid 
residue 297 would disrupt the Sdccag1 interaction with MeCP2, all of which could affect 
MeCP2’s role in RNA biogenesis. 
 
MeCP2 interacts with specific mRNAs in vivo  
Several lines of evidence implicate MeCP2 is associated with mRNA biogenesis 
in vivo; MeCP2 binds RNA in vitro (Jeffery and Nakielny, 2004), is part of a 
ribonucleoprotein complex with YB-1 in cell culture (Young et al., 2005), MeCP2 
knock-out mice show misspliced transcripts in the brain (Young et al., 2005), it has been 
identified as a transcriptional activator at the majority of gene promoters it has been 
shown to regulate (Chahrour et al., 2008), and here MeCP2 is shown to interact with the 
splicing factor Prpf3.  To determine if MeCP2 interacts with the RNA transcripts of 
genes it regulates in vivo, RNA immunoprecipitations (RIP) were performed.  Using anti-
HA antibodies on HT-22 (HA-MeCP2) cell lysates, mRNAs for the MeCP2 regulated 
gene Cdk10 were able to be specifically RIP’ed (Figure 2.17A).  Assaying the IP’s by 
RT-PCRs using oligonucleotide primers designed to amplify across exon junctions of 
Cdk10 show MeCP2 is associated with the spliced form of the gene, while MeCP2 is not 
associated with the Casc3 gene transcript (Figure 2.17A).  The RIPs were RNase 
sensitive confirming that RNA and not DNA was IP’ed.  Interestingly, RT-PCR for RIPs 
using primers for Cdk10 show what appears to be pre-mRNA by size and RNase 
sensitivity; however, unlike the spliced forms these pre-mRNA products, while generally 
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consistent, were not observed in 100% of the RT-PCR analyses for Cdk10 (Figure 2.17A 
top).  
 To investigate if Prpf3 was part of the HA-MeCP2/mRNA complex, a RIP and 
Re-RIP approach was implemented.  Anti-HA antibodies were used to RIP HA-
MeCP2/mRNA complexes from HT-22 (HA-MeCP2) cell lysates, the bound complexes 
were eluted from the HA antibodies intact using DTT to disrupt the IgG structure, and 
then anti-Prpf3 antibodies were used to Re-RIP.  Therefore, any RNAs present in the Re-
RIP must have been associated with both MeCP2 and Prpf3.  RT-PCR analysis showed 
that RIP for HA-MeCP2 and subsequent Re-RIP for Prpf3 protein IP-ed mRNA for 
Cdk10, indicating that both proteins are in fact associated with this target mRNA (Figure 
2.17B), supporting their being in a complex in vivo. 
 To further support MeCP2 RIP results, experiments were preformed to determine 
if MeCP2 interacts with transcriptionally active Xenopus lampbrush chromosome (LBC) 
spreads. Actively transcribed LBC loops from Xenopus oocytes are surrounded by an 
observable ribonucleoprotein (RNP) matrix, composed of RNA polymerase II and 
elongating transcripts packed together with processing factors that give rise to RNP 
fibrils (Austin et al., 2009; Gall et al., 1999) (Figure 2.18 - Phase Contrast).  Staining of 
the lampbrush chromosomes with xNF7, a factor known to be associated with actively 
transcribed LBC loops (Beenders et al., 2007), indicates active transcription on one 
isolated loop (Figure 2.18 - XNF7, white arrow).  Microinjection of HA tagged human 
MeCP2 (hMeCP2-HA) mRNA into oocytes, and subsequent LBC spread shows that 
MeCP2 interacts with both the highly condensed axis (Figure 2.18 - MeCP2) and actively 
transcribed loops (Figure 2.18 - MeCP2, white arrow) by immunofluorescence.  
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Immunofluorescent staining of uninjected controls show antibodies are specifically 
staining hMeCP2-HA (Figure 2.19).  This data further suggests a role for MeCP2 in 
mRNA processing.          
  
DISCUSSION 
 
MeCP2 has been characterized as a multifunctional protein using a variety of 
techniques and from numerous cellular contexts, however only the biochemical 
characteristics of the endogenous MeCP2 protein in the brain are relevant to RTT.  
Structural studies indicate that MeCP2 contains at least six structurally distinct domains 
(Adams et al., 2007).  Mutations generally manifested as point mutations resulting in a 
single missense or nonsense amino acid change have been identified in all domains of 
MECP2 from RTT patients (www.rettsyndrome.org/), suggesting that all domains are 
critical for MeCP2 function (Hite et al., 2009; Moore et al., 2005).  Although all these 
mutations produce clinical RTT pathology, certain mutations are more strongly 
associated with particular symptoms and disease severity suggesting that all RTT 
mutations in MECP2 are not equal, with some potentially being more disruptive towards 
MeCP2’s many functions (Jian et al., 2005; Neul et al., 2008).  However, the underlying 
mechanisms of how these myriad mutations lead to RTT pathophysiology remain unclear 
due to a lack of understanding toward the complete scope of MeCP2’s normal function in 
the brain.  Here, we begin to reveal molecular mechanisms of MeCP2 function relevant to 
RTT through the identification of four distinct brain-derived MeCP2 protein pools, 
agreeing with the functional data proposing multiple roles for MeCP2 (Hite et al., 2009).  
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Characterization of one of these complexes as containing MeCP2, Pprf3, Sdccag1, and 
mRNA strongly complements previously published data that MeCP2 is involved in 
mRNA splicing, and this activity is disrupted by certain RTT mutations (Young et al., 
2005). 
We have found MeCP2 can associate with RNA by RIP and on transcriptionally 
active loops in Xenopus LBC spreads.  MeCP2’s association with Prpf3, a major 
component of the spliceosome, supports MeCP2 as having a role in modulating mRNA 
splicing; exactly what that role might be is still not clear.  Interestingly, a recent study 
suggests that differential gene body methylation may play a role in transcript splicing 
(Laurent et al.).  By identifying the genome wide methylation status in multiple human 
cell types, the group found that exons were more highly methylated than introns, and that 
there were sharp transitions of methylation at exon-intron boundaries (Laurent et al.).  
Based on what is known about MeCP2 and Prpf3 independently, potentially MeCP2’s 
direct interaction with Prpf3 could function in splice site selection.  Prpf3 is one of 
multiple associated proteins of the U4/U6.U5 tri-snRNP complex that is recruited to the 
splice site to form and stabilize the functional spliceosome, and is essential for pre-
mRNA splicing (Brown and Beggs, 1992; Horowitz et al., 1997; Lauber et al., 1997; 
Wang et al., 1997). Importantly, MeCP2 can bind RNA directly (Jeffery and Nakielny, 
2004), and has been implicated as a regulator of alternative splicing in the HeLa and 
Neuro2A cell lines through an RNA-dependent interaction with YB-1 (Young et al., 
2005), a protein known to participate in splicing of mRNAs (Philips et al., 1998; 
Stickeler et al., 2001).  While we were unable to detect YB-1 as a component of the 
MeCP2/Prpf3/Sdccag1 complex in brain, it is inefficient to inhibit the highly active and 
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stable RNases that would abolish any YB-1/RNA/MeCP2 interaction during purification 
so we cannot rule out that YB-1 could be part of a larger RNA-dependent alternative 
splicing complex.  Nevertheless, a direct interaction of MeCP2 and Prpf3 further supports 
a role for MeCP2 in mRNA splicing regulation. 
Sdccag1 was originally identified from colon cancer patients by a serological 
analysis of recombinant cDNA expression libraries (SEREX) (Scanlan et al., 1998) and 
later identified as a tumor suppressor by its ability to cause cell cycle arrest in a non-
small-cell lung cancer cell line (Carbonnelle et al., 2001).  The significance of finding 
Sdccag1 as part of the MeCP2-Prpf3 complex can only be implied due to the limited 
information on its function in vertebrates and Drosophila.  Bioinformatically the Sdccag1 
protein contains a predicted RNA-binding domain homologous to a eukaryotic small 
nuclear ribonucleoprotein (Marchler-Bauer et al., 2009), suggesting the capacity to 
function in mRNA splicing.  Functionally, the Drosophila Sdccag1 homolog Caliban, has 
been shown to interact with and mediate the nuclear export of the Prospero homeodomain 
transcription factor (Prox in mammals) and this interaction and function is conserved in 
mammalian cells (Bi et al., 2005).  This raises the possibility that the 
MeCP2/Prpf3/Sdccag1 complex may not only be involved in splicing mRNA, but also 
transporting mRNAs.  Consistent with this model, MeCP2 has been shown to have both a 
nuclear and cytoplasmic localization in neuronal cell lines (Miyake and Nagai, 2007).  
Notably, Mecp2308/Y mice, which produce a truncated form of MeCP2 and reproduce 
many of the classical features of RTT (Moretti et al., 2005; Shahbazian et al., 2002a), 
have been shown to have multiple genes that are abnormally spliced in the brain (Young 
et al., 2005).  This suggests the C-terminal portion of MeCP2, which we have identified 
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as the putative Sdccag1 interaction domain, plays a critical role in regulating alternative 
splicing. 
MeCP2 is present at the promoter of many actively transcribed genes (Yasui et al., 
2007), and activates a majority of genes it regulates in the mouse hippocampus (Chahrour 
et al., 2008).  MeCP2’s ability to bind chromatin in vivo appears to be dynamically 
regulated by phosphorylation in the brain (Chen et al., 2003; Tao et al., 2009).  
Experimentally, MeCP2 is known to bind RNA in vitro with a similar affinity as to 
methylated DNA and that the two activities are mutually exclusive (Jeffery and Nakielny, 
2004).  Thus, MeCP2 at an active promoter or within the body of a transcribed gene 
would be well positioned spatially upon its release to interact with the transcripts of the 
genes it activates and influence splice site selection.  Therefore, it is reasonable to 
propose that MeCP2 activated genes would also be targets for splicing regulation by a 
MeCP2 containing complex.  Supporting this model, RNA transcripts from Cdk10, a 
gene positively regulated by MeCP2 binding at its promoter (Chahrour et al., 2008) and 
abnormally spliced in Mecp2308/Y mice (Young et al., 2005), were associated with both 
MeCP2 and Prpf3 in vivo. 
  Considering the range of mutations throughout MECP2 in RTT, it is not 
surprising that many RTT mutations are within, or predicted to affect both the Prpf3 and 
Sdccag1 binding domains, disrupting the MeCP2/Prpf3/Sdccag1 complex and 
presumably MeCP2-mediated splicing regulation and mRNA transport.  With MeCP2 
emerging as a multifunctional protein and its biological role in RTT unclear, identifying 
biochemically distinct pools of Mecp2 in the brain containing novel MeCP2 interacting 
proteins is a valuable tool towards an understanding MeCP2 function and its dysfunction 
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in RTT.  This study adds to the mounting evidence indicating that one such critical 
function of MeCP2 in the brain involves RNA biogenesis.   
 
MATERIALS AND METHODS 
 
Antibodies and western blot analysis  
Protein samples were separated by SDS-PAGE and transferred to ECL nylon 
membrane (GE Healthcare) for western blotting by standard methods.  For each 
experiment, the western blotting images presented are from the same exposure on the 
same piece of film, linearly adjusted for brightness in Adobe Photoshop.  The anti-
MeCP2 7-18 antibody is a rabbit polyclonal derived from bacterially expressed 
recombinant protein encoding amino acid residues 310 to 388 of human MeCP2e2 
isoform.  The anti-MeCP2 3998 antibody is a rabbit polyclonal derived from bacterially 
expressed recombinant protein encoding the full length human MeCP2e2 isoform.  
Antibodies were used at the following concentrations: anti-MeCP2 7-18, 1:2000; anti-
MeCP2 3998 , 1:1000; anti-MeCP2 (Upstate 07-013) 1:1000; Anti-PRP3 (MBL D171-3) 
1:2000; and Anti-HA High Affinity (Roche 14559100) at 1:1000. 
 
Molecular biology and generation of plasmid constructs 
RNA was purified from rat brain tissue or HeLa cells using Trizol Reagent 
(Invitrogen) per manufacturers’ instructions.  All cDNAs were generated using 
SuperScript III One-Step RT-PCR with Platinum Taq (Invitrogen).  All PCRs were 
performed with Phusion polymerase (New England Biolabs) and cloned into pGEM-T 
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easy (Promega) for sequencing prior to sub-cloning into pGEX-5X1 (GE Life sciences), 
pCDNA 3.1 (Invitrogen), or the pCDNA 3.1 HA vector (Matzat et al., 2008).  All 
primers are listed in Table 1.  All human MeCP2 constructs were generated from the 
human MECP2E2 cDNA (NM_004992).  To generate constructs for in vitro synthesized 
proteins, cDNAs were PCR amplified using primers listed in Table 1 and sub-cloned into 
the specified restriction sites of pCDNA 3.1.  Rat cDNAs were sub-cloned between NotI 
and XhoI; the human Prpf3 cDNA clone was sub-cloned between EcoRI and XhoI; the 
human full-length MeCP2 was amplified from full-length cDNA and sub-cloned between 
NotI and XhoI.  Constructs for bacterially generated GST fusion proteins were PCR 
amplified from full-length cDNAs, sub-cloned into the specified restriction sites of 
pGEX5-X1 using primers listed in Table 1.  Rat GST-Prpf3 was sub-cloned between 
BamHI and XhoI.  The rat and human GST-MeCP2 full-length, GST-MeCP2 deletions, 
and human GST-MeCP2 RTT cDNAs were sub-cloned between EcoRI and XhoI.   The 
pCDNA3P HA-MeCP2 vector was created by PCR amplification of full-length human 
MeCP2, digestion and sub-cloning into the NotI and XhoI restriction sites of the 
pCDNA3.1 HA vector and subsequent digestion with NdeI and XhoI for cloning of the 
HA-MeCP2 fragment into the pCDNA3P puromycin vector.  
  
Cell culture and immunofluorescent staining 
 HT-22 cells (a gift from Dr. Stephanie Ceman) were transfected with pCDNA 
3.1P HA-MeCP2 using Fugene HD transfection reagent (Roche).  Stable integrants were 
selected as pools in puromycin (1μg/ml), and maintained in Dulbecco’s modified Eagle’s 
medium (Biowhittaker) supplemented with 10% fetal bovine serum, glutamine, 
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antibiotics and puromycin.  Immunofluorescent staining of stably transfected HA-MeCP2 
Ht-22 cells was preformed essentially as previously described (Levesque et al., 2001).  In 
brief, cells grown on poly-d-lysine coated coverslips were washed in PBS, fixed with 4% 
formaldehyde and 4% glucose in PBS for 10 min at RT.  Coverslips were washed 3 times 
in PBS and permeabilized with 0.2% TritonX-100 in PBS for 20 min at RT.  Cells were 
then washed 3 times in PBS with 0.1% tween-20 and subsequently incubated in Block 
(2% BSA, 2% FBS, 0.1% Tween-20 in 1X PBS) for 1 hour at RT.  Overnight incubation 
of coverslips in primary antibody (anti-HA High Affinity (Roche 14559100), 1:200 in 
Block) were preformed in a humidified box at 4°C.  Cells were washed 3 times in PBS 
with 0.1% tween-20 and incubated with anti-RAT rhodamine (Jackson Labs) for 1 hour 
at RT.  Coverslips were washed 3 times in PBS with 0.1% tween-20 and stained with 
DAPI, mounted.    
 
Purification of endogenous MeCP2 
Rat brain nuclei were isolated generally as described (Lewis et al., 1992).  Adult 
rat brains (n=200 total per preparation) were obtained (Pel-Freez Biologicals), thawed on 
ice, and homogenized with 14 strokes of a loose pestle in a 40ml Dounce homogenizer 
(Wheaton) in ice-cold HB (20mM Hepes pH 7.9, 25mM KCl, 0.5mM EGTA, 1mM 
EDTA, 2M sucrose, 10% glycerol, freshly added 0.5mM spermidine, 0.15mM spermine, 
1μg/ml leupeptin, 1μg/ml pepstatin, 1μg/ml aprotinin).  The homogenate (26ml/tube) was 
layered onto an 8ml cushion of HB and centrifuged in a SW28 rotor at 24,000 rpm for 1 
hr at 4°C.  Pelleted nuclei were resuspended in Buffer A (20mM Hepes pH 7.5, 1.5mM 
MgCl2, 1mM EGTA, 10% glycerol, freshly added 0.5mM DTT, 1 μg/ml leupeptin, 
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1μg/ml pepstatin, 1μg/ml aprotinin) supplemented with 350mM NaCl (A-350) and 
extracted with rotation for 30 min at 4°C.  Insoluble material was removed by 
centrifugation at 200,000 x g for 20min at 4°C.  The supernatant was diluted with Buffer 
A to reduce the NaCl concentration below 200mM NaCl and used as a soluble protein 
source for chromatography.   
All chromatography was preformed using an AKTA-FPLC (GE Healthcare) and 
FPLC columns (GE Healthcare) at 4°C in Buffer A with indicated concentrations of NaCl.  
Soluble protein (130 mg) was fractionated over a MonoQ10/10 column with bound 
protein eluted by a 20 column volume (cv) linear salt gradient from 100mM to 1000mM 
NaCl, collecting 1 cv fractions.  Soluble protein (29 mg) from MonoQ flow through was 
fractionated over MonoS5/5 with bound protein eluted by a 20 column volume (cv) linear 
salt gradient from 100mM to 1000mM NaCl, collecting 1 cv fractions.  MeCP2 
containing fractions centered at 450 mM NaCl (QF) were combined and loaded onto a 
1ml Heparin FastFlow column and eluted with a 10 cv linear gradient from 450mM to 
1000mM, collecting 1 cv fractions.  Pooled heparin column fractions containing MeCP2 
were applied to a 110 ml superose 6 column and fractionated in buffer A-150 with 0.1% 
Trition-X100.  Subsequently, 0.5 ml of each fraction was trichloriacetic acid-precipitated, 
subjected to SDS-PAGE, and used for Western blotting or silver staining (Sigma Aldrich 
– PROTSIL1-1KT).  The silver-stained polypeptide corresponding by size to MeCP2 
(and by western) was excised and analyzed by mass spectrometry.  The MeCP2 
containing fractions (QB1/2) peaking at 230mM NaCl were pooled (1.56 mg), diluted 
with buffer A and fractionated over MonoS5/5 with bound protein eluted by a 20 column 
volume (cv) linear salt gradient from 250mM to 1000mM NaCl, collecting 1 cv fractions.  
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The MeCP2 containing fractions peaking at 550 mM NaCl (QB2) were combined and 
loaded onto a 1ml Heparin FastFlow column and eluted with a 10 cv linear gradient from 
450mM to 1000mM, collecting 1 cv fractions.  Pooled heparin column fractions 
containing MeCP2 were applied to a 110 ml superose 6 column and fractionated in buffer 
A-150 with 0.1% Trition-X100.  Subsequently, 0.5 ml of each fraction was trichloriacetic 
acid-precipitated, subjected to SDS-PAGE, and used for Western blotting or silver 
staining (Sigma Aldrich – PROTSIL1-1KT).  Silver-stained polypeptide bands precisely 
cofractionating with MeCP2 (by western) were excised and analyzed by mass 
spectrometry.      
For the nuclease treatment experiments, MonoQ eluted MeCP2 was dialyzed 
against buffer A-100 containing 1mM CaCl2, 10mM MgCl2 and without EGTA then 
either treated with or without 500 units of Benzonase nuclease (Sigma) for 30 min. at 
37°C, and re-tested for ability to bind the MonoQ resin. 
For the CIP treatment experiment, MonoQ eluted MeCP2 was dialyzed against 
buffer A-100 containing 1mM CaCl2, 10mM MgCl2 and without EGTA then either 
treated with 60 units of CIP (NEB) for 30 min. at 37°C, and re-tested for ability to bind 
the MonoQ resin. 
 
Mass spectrometry 
All mass spectrometry was carried out at the Protein Sciences Facility at the 
University of Illinois.  FPLC purified fractions were separated by SDS-PAGE, visualized 
by mass spectrometry compatible silver staining and polypeptide bands were excised.  
Gel slices were destained (50% acetonitrile, 25 mM ammonium bicarbonate) then 
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digested in 25 μl of Sequencing Grade Trypsin (12.5 nanogram/microliter in 25 mM 
ammonium bicarbonate, G-Biosciences St. Louis, MO) using a CEM Discover 
Microwave Digestor (Mathews, NC) for 15 min at 55°C (60W).  Digested peptides were 
extracted using 50% acetonitrile with 5% formic acid, dried in a Savant SpeedVac and 
suspended in 13 μl of 5% acetonitrile containing 0.1% formic acid with10 μl of sample 
used for mass spec analysis.  The mass spectrometer used was Waters quadrupole time-
of-flight mass spectrometer (Q-ToF) connected to a Waters nano-Acquity UPLC.  The 
column used was Waters Atlantis C-18 (0.075 mm x 150 mm) with a flow rate of 250 
nanoliters per minute.  Peptides were eluted using a linear gradient of water/acetonitrile 
containing 0.1% formic acid (0-60% B) in 60 minutes.  The mass spectrometer was set 
for data dependent acquisition, ms/ms was performed on the most abundant four peaks at 
any given time.  Data analysis was performed using Waters Protein Lynx Global Server 
2.2.5, Mascot (Matrix Sciences) and BLAST against NCBI NR database. 
 
GST pull-down assay 
Recombinant GST-fusion proteins were generated in E. coli BL-21(DE3) cells 
(Stratagene) according to manufacture’s (GE Healthcare) protocol.  In vitro 
transcribed/translated proteins radiolabeled with [35S]methionine were produced using the 
T7 TnT Quick Coupled Transcription/Translation System (Promega).  GST pull-down 
assays were preformed by incubation of Glutathione Sepharose 4B (GE Healthcare) 
bound GST-fusion proteins and in vitro synthesized candidate proteins in 1X PBS with 
1mM DTT, 0.1% Tween-20, 1mM PMSF, 1μg/ml leupeptin, 1μg/ml pepstatin, and 
1μg/ml aprotinin.  Reactions were rotated overnight at 4°C, with or without 250 units of 
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Benzonease nuclease, washed 6 times in 1X PBS with 0.1% NP-40 with interacting 
[35S]methionine labeled proteins separated by SDS-PAGE and visualized by 
autoradiography. 
 
Co-immunoprecipitation (Co-IP) 
 Co-IPs from fractionated brain extracts were carried out as follows:  Protein A 
Dynabeads (Invitrogen) were blocked with BSA and incubated with either anti-MeCP2 
3998 or IgG in fractionated material, diluted to 100mM NaCl with Buffer A0, for 2 hrs at 
4°C with rotation.  IPs were washed three times with buffer A225, eluted with Laemmli 
buffer, separated by SDS-PAGE and subjected to Western blot analysis.  The anti-
MeCP2 3998 antibody is a rabbit polyclonal derived from bacterially expressed 
recombinant protein encoding the full length human MeCP2e2 isoform.   
Co-IPs were carried out essentially as previously described (Young et al., 2005).  
HT-22 cells (8 x 106) stably expressing HA-MeCP2 were lysed in 1ml of IPH buffer (50 
mM Tris-HCl, pH 8.0, 150mM NaCl, 5mM EDTA, 0.5% NP-40, 1μg/ml leupeptin, 
1μg/ml pepstatin, 1μg/ml aprotinin) at 4°C for 30min and debris removed by 
centrifugation for 15min at 16,000 x g at 4 °C.  Lysates were precleared with protein A 
agarose then incubated for 4 hrs with anti-HA (Sigma, E6779) or irrelevant IgG with 
protein A agarose beads (Santa Cruz Biotechnologies) at 4°C with rotation.  Nuclease 
treatment was preformed by re-suspension of protein bound beads with 125 units of 
Benzonase for 10 min at 37 °C.  Precipitates were washed three times with IPH buffer, 
eluted with Laemmli buffer, separated by SDS-PAGE and subjected to Western blot 
analysis.   
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RNA immunopreciptation 
RNA IP was preformed as previously described with modifications (Lin et al., 
2005).  HT-22 cells (1 x 108) stably expressing HA tagged MeCP2 were collected and 
washed and resuspended in 4ml 1X PBS.  0.4 ml of crosslinking buffer (100 mM NaCl, 1 
mM EDTA, 0.5 mM EGTA, 50 mM HEPES, 11% formaldehyde) was added to 
resuspended cells and incubated at RT for 30 min with rocking.  Quench with 0.22 ml of 
2.5 M glycine pH 7.0 for 5 min at RT.  Centrifuge at 1367 x g for 5 min at 4 °C to pellet 
and wash with 1X PBS.  Lyse cells in 1 ml FA buffer (50 mM HEPES-KOH pH 7.5, 140 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 1 μg/ml 
leupeptin, 1μg/ml pepstatin, 1μg/ml aprotinin, 100 units/ml RNasin [Promega]) by 
sonication (25% power, 50% duty) for 10 pulses of 30 sec with rest on ice.  The lysed 
cells were treated with DNase I (Promega) by adding 25 mM MgCl2, 5 mM CaCl2, 6 μl 
RNasin and 200 units DNase I for 30 min at 37 °C.  Extracts were cleared by 
centrifugation 15 min at 14,000 RPM in an Eppendorf 5415C centrifuge at 4 °C.  100 μl 
of cleared extract are diluted with 900 μl of ChIP dilution buffer (50 mM HEPES pH 7.5, 
140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40).  Diluted extracts were 
incubated with either HA antibody or non-specific IgG with 4 μl RNasin, for 12 hours, 
rotating at 4 °C.  40 μl of ChIP buffer equilibrated protein A or G Dynabeads (Invitrogen) 
were then added for 1 hour rotating at 4 °C, then washed 3 x 10 min with wash buffer (50 
mM Tris pH 7.4, 500 mM NaCl, 1% Triton X-100, 0.1% SDS, 100 units/ml RNasin).  
For Re-RIP experiments, beads were washed and bound immune-RNA complexes were 
released in 20mM dithiothreitol solution for 30 min at 37°C and resuspended in one 
volume of ChIP dilution buffer for ReRIP with antibody for PRPF3 and washed as before.  
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After final wash, beads were brought up in 200 μl of elution buffer (200 mM NaCl, 50 
mM Tris pH 7.4, 20 μg Proteinase K) and digested for 1 hour at 42°C, and then cross-
links reversed for 5 hours at 65°C.  Samples were extracted with acid equilibrated (pH 
4.8) phenol:chloroform (5:1) and ethanol precipitated.  Precipitated material was 
resuspended in 50 μl DEPC-H2O and 1 μl used for RT-PCR analysis with SuperScript III 
One-Step RT-PCR with Platinum Taq (Invitrogen) according to manufactures protocol.  
RT-PCR primers for mRNA targets Cdk10, Casc3 and Frg1 are listed in Table 1.   
Results were analyzed by electrophoresis on a 2% agarose gel.   
 
Xenopus LBC spreads and immunofluorescent staining   
Female adult frogs (Xenopus laevis) were anesthetized in 0.15% tricaine 
methanesulfonate (Sigma), and small fragments of ovary were surgically removed. Non-
defolliculated oocytes were used for isolation of nuclei, and the nuclear spreads were 
performed as previously described (Patel et al., 2008; Patel et al., 2007). The samples 
were fixed with 2% paraformaldehyde in PBS plus 1 mM MgCl2 for 1 hr at room 
temperature. After fixation, the nuclear spreads were rinsed in PBS and blocked with 
0.5% bovine serum albumin (Sigma-Aldrich) plus 0.5% gelatin (from cold-water fish) in 
PBS for 10 min. Spreads were incubated with primary antibody, anti-HA antibody MAb 
3F10 (Roche, Mannheim, Germany), used at a concentration of 20 ng/ μl, for 1 h at RT, 
washed for 30 min with two changes of PBS, incubated in secondary antibody, Alexa 
488-labeled-goat anti-mouse IgG (Invitrogen, Carlsbad, CA), at a concentration of 2.5 
μg/ml and incubated for 1 hr at RT, and washed again for 30 min with two changes of 
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PBS. Spreads were incubated with 1 μM Syto61 (Invitrogen) in PBS for 20 min at RT 
and briefly rinsed in PBS before mounting in 50% glycerol/PBS. 
 
Microscopy 
 Fluorescent images were taken by fluorescence microscopy using an Olympus 
BX60 microscope equipped with a SpotRT monochrome model 2.1.1 camera and Spot 
Advanced software (Diagnostic Instruments, Sterling Heights, MI). 
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FIGURES & TABLES 
 
 
 
Figure 2.1:  Brain-derived nuclear Mecp2 exists in multiple biochemically distinct pools.  
(A) Chromatographic separation of crude rat brain nuclear extract by strong anion 
exchange (MonoQ resin) results in three distinct pools of Mecp2 as indicated by western 
blot using the MeCP2 7-18 antibody.  The majority of Mecp2 does not bind the column 
(QF), while the bound Mecp2 elutes in two peaks, at 230mM NaCl (QB1/2) and 450mM 
NaCl (QB3).  (B) QB1/2 MeCP2 elutes in two peaks from the MonoS column, the first at 
400mM NaCl (QB1) and the second eluting at 550mM NaCl (QB2).     
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Figure 2.2:  Anti-MeCP2 antibodies react specifically with MeCP2 from multiple protein 
sources. Antibodies against MeCP2 were used in western blotting of brain nuclear 
extracts from cow, mouse, and rat, and nuclear extracts from human lymphoblast 
expressing the RTT R168X truncation to show their specificities. The Jones lab generated 
anti-MeCP2 3998 (left panel) (Harikrishnan et al., 2005), and anti-MeCP2 7-18 (center 
panel) were compared with an anti- MeCP2 antibody purchased from Upstate Biotech 
(right panel). All three antibodies react with a single polypeptide migrating at ~80 kDa, 
consistent with MeCP2’s known migration on SDS-PAGE, in brain nuclear extracts (2 or 
20 _g/lane) from cow, mouse, and rat. These antibodies show no reactivity to any 
polypeptides in the human MeCP2 RTT R168X extracts by western blot analysis. These 
data confirm that the anti-MECP2 7-17 antibody used in this study is specific for MeCP2. 
Load controls using an antibody for Sin3A are shown above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67
 Mono Q  Flow Thru 
Mono S 
100 
700 350-650 
100 
1000 600-800 
Heparin 
150 150 
500-400kDa 
Superose 6 
 
 
Figure 2.3:  QF MeCP2 purification scheme.  MonoQ flow through MeCP2 was purified 
using a four-step process including the MonoQ strong anion exchange resin, MonoS 
strong cation exchange resin, Heparin affinity resin and by Superose 6 gel filtration. 
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MeCP2 MonoQ flow-through (QF):  Sequence coverage 47% 
MVAGMLGLRKEKSEDQDLQGLKEKPLKFKKVKKDKKEDKEGKHEPLQPSAHHSAEPAEAGKAETSESSGSAPAVPEASASP
KQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG
SPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTGRPKAAASEGVQVKRVLEKSPGKLLVKMPFQASPGGKGEGGGATTSAQ
VMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVS
TLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHAESPKAPMPLLPPPPPPEPQSSEDPISPPEPQDLSSSICK
EEKMPRAGSLESDGCPKEPAKTQPMVAAAATTTTTTTTTVAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS 
 
MeCP2 MonoQ bound 2 (QB2):  Sequence coverage 23% 
MVAGMLGLRKEKSEDQDLQGLKEKPLKFKKVKKDKKEDKEGKHEPLQPSAHHSAEPAEAGKAETSESSGSAPAVPEASASP
KQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG
SPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTGRPKAAASEGVQVKRVLEKSPGKLLVKMPFQASPGGKGEGGGATTSAQ
VMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVS
TLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHAESPKAPMPLLPPPPPPEPQSSEDPISPPEPQDLSSSICK
EEKMPRAGSLESDGCPKEPAKTQPMVAAAATTTTTTTTTVAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS 
 
MeCP2 MonoQ bound 3 (QB3):  Sequence coverage 33% 
MVAGMLGLRKEKSEDQDLQGLKEKPLKFKKVKKDKKEDKEGKHEPLQPSAHHSAEPAEAGKAETSESSGSAPAVPEASASP
KQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRG
SPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTGRPKAAASEGVQVKRVLEKSPGKLLVKMPFQASPGGKGEGGGATTSAQ
VMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVS
TLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHAESPKAPMPLLPPPPPPEPQSSEDPISPPEPQDLSSSICK
EEKMPRAGSLESDGCPKEPAKTQPMVAAAATTTTTTTTTVAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS 
 
Figure 2.4:  Mass spectrometry peptide identifications (in red) for rat MeCP2 from the 
QF, QB2, and QB3 pools of MeCP2. 
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Figure 2.5:  The QF pool of Mecp2 does not co-purify with other proteins.  (Upper 
panel) Silver-stain analysis of the Superose 6 fractionation of the QF Mecp2 pool. (Lower 
panel) Western blot analysis of Superose 6 fractions showing Mecp2 protein peaks in 
fraction 9.  
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Figure 2.6:  (A) MonoQ resin bound fractions of Mecp2 were treated with (+) or without 
Benzonase nuclease and tested for ability to re-bind the Mono Q.  Western blot analysis 
for Mecp2 of MonoQ flow thru, wash, and 1000mM NaCl step elution shows Benzonase 
treatment does not affect binding of MeCP2 to the Mono Q column.  (B) Plasmid spiked 
MonoQ fractions treated with benzonase (+) or untreated (-) in parallel served as controls 
for Benzonase treatment.  (C)  MonoQ resin bound fractions of Mecp2 were treated with 
or without calf intestinal phosphatase (CIP) and tested for ability to re-bind the Mono Q.  
Western blot analysis for Mecp2 of MonoQ flow through (FT), and column bound step 
fractions shows CIP treatment does not affect binding of MeCP2 to the Mono Q column.   
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Figure 2.7:  QB2 MeCP2 purification scheme.  MeCP2 peak fractions were purified 
using a four-step process including the MonoQ strong anion exchange resin, MonoS 
strong cation exchange resin, Heparin affinity resin and by Superose 6 gel filtration. 
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Figure 2.8:  The QB2 pool of Mecp2 co-purifies with 6 candidate proteins including 
Prpf3. (Upper panel) Silver-stain analysis of the Superose6 fractionation of the QB2 
Mecp2 pool.  (Lower panel) Western blot analysis of Superose 6 fractions shows Mecp2 
protein peaks in fractions 7 and 8, precisely co-fractionating with Prpf3 protein. 
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Figure 2.9:  Identification of candidate Mecp2 complex proteins.  (a) Polypeptides from 
silver stained Superose6 fractions were excised and identified by mass spectrometry 
(tandem LC MS/MS). Mecp2 and two other nuclear proteins, Sdccag1 and Prpf3 were 
identified as well as components of a translation initiation complex. (b) Mass 
spectrometry peptides identifying Mecp2, Prpf3, and Sdccag1. 
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EIF2S1  [eukaryotic translation initiation factor 2, subunit 1] Sequence Coverage: 33% 
MPGLSCRFYQHKFPEVEDVVMVNVRSIAEMGAYVSLLEYNNIEGMILLSELSRRRIRSINKLIRIGRNECVVVIRVDKEKGYID
LSKRRVSPEEAIKCEDKFTKSKTVYSILRHVAEVLEYTKDEQLESLFQRTAWVFDDKYKRPGYGAYDAFKHAVSDPSILDSL
DLNEDEREVLINNINRRLTPQAVKIRADIEVACYGYEGIDAVKEALRAGLNCSTETMPIKINLIAPPRYVMTTTTLERTEGLSV
LNQAMAVIKEKIEEKRGVFNVQMEPKVVTDTDETELARQLERLERENAEVDGDDDAEEMEAKAED 
 
EIF2S2  [eukaryotic translation initiation factor 2, subunit 2] Sequence Coverage: 30% 
MSGDEMIFDPTMSKKKKKKKKPFMLDEEGDAQTEETQPSETKEVEPEPAEEKDVEADEEDSRKKDASDDLDDLNFFNQKK
KKKKTKKIFDIDEAEEAIKDVKIESDAQEPAEPEDDLDIMLGNKKKKKKNVKFPDEDEILEKDEALEDEDSKKDDGISFSNQT
GPAWAGSERDYTYEELLNRVFNIMREKNPDMVAGEKRKFVMKPPQVVRVGTKKTSFVNFTDICKLLHRQPKHLLAFLLAEL
GTSGSIDGNNQLVIKGRFQQKQIENVLRRYIKEYVTCHTCRSPDTILQKDTRLYFLQCETCHSRCSVASIKTGFQAVTGKRAQ
LRAKAN 
 
EIF2S3  [eukaryotic translation initiation factor 2, subunit 3] Sequence Coverage: 37% 
MAGGEAGVTLGQPHLSRQDLATLDVTKLTPLSHEVISRQATINIGTIGHVAHGKSTVVKAISGVHTVRFKNELERNITIKLGY
ANAKIYKLDDPSCPRPECYRSCGSSTPDEFPTDIPGTKGNFKLVRHVSFVDCPGHDILMATMLNGAAVMDAALLLIAGNESC
PQPQTSEHLAAIEIMKLKHILILQNKIDLVKESQAKEQYEQILAFVQGTVAEGAPIIPISAQLKYNIEVVCEYIVKKIPVPPRDFT
SEPRLIVIRSFDVNKPGCEVDDLKGGVAGGSILKGVLKVGQEIEVRPGIVSKDSEGKLMCKPIFSKIVSLFAEHNDLQYAAPGG
LIGVGTKIDPTLCRADRMVGQVLGAVGALPEIFTELEISYFLLRRLLGVRTEGDKKAAKVQKLSKNEVLMVNIGSLSTGGRVS
AVKADLGKIVLTNPVCTEVGEKIALSRRVEKHWRLIGWGQIRRGVTIKPTVDDD 
 
PRP3  [PRP3 pre-mRNA processing factor 3 homolog] Sequence Coverage: 9%  
MALSKRELDELKPWIEKTVKRVLGFSEPTVVTAALNCVGKGMDKKKAADHLKPFLDDSTLRFVDKLFEAVEEGRSSRHSKS
SSDRSRKRELKEVFGDDSEISKESSGVKKRRIPRFEEVEEEPEVIPGPPSESPGMLTKLQIKQMMEAATRQIEERKKQLSFISPPA
PQPKTPSSSQPERLPIGNTIQPSQAATFMNDAIEKARKAAELQARIQAQLALKPGLIGNANMVGLANLHAMGIAPPKVELKDQ
TKPTPLILDEQGRTVDATGKEVELTHRMPTLKANIRAVKREQFKQQLKEKPSEDMESNTFFDPRVSIAPSQRQRRTFKFHDKG
KFEKIAQRLRTKAQLEKLQAEISQAARKTGIHTSTRLALIAPKKELKEGDIPEIEWWDSYIIPNGFDLTEENPKREDYFGITNLV
EHPAQLNPPVDNDTPVTLGVYLTKKEQKKLRRQTRREAQKELQEKVRLGLTPPPEPKVRISNLMRVLGTEAVQDPTKVEAH
VRAQMAKRQKAHEEANAARKLTAEQRKVKKVKKLKEDISQGVHISVYRVRNLSNPAKKFKIEANAGQLYLTGVVVLHKD
VNVVVVEGGPKAQRKFKRLMLHRIKWDEQTSNTKGDDDEESDEEAVKKTNKCVLVWEGTAKDRSFGEMKFKQCPTENM
AREHFKKHGAEHYWDLALSESVLESTD 
 
ABCF1  [ATP-binding cassette sub-family F member 1] Sequence Coverage: 32% 
MPKGPKQQPPEPEWIGDGEGTSPADKVVKKGKKDKKTKKTFFEELAVEDKQAGEEEKLQKEKEQQQQQQQQKKKRDTRK
GRRKKDVDDDDDGDERVLMERLKQLSVPASDEEDEVPVPVPRGRKKAKGGNVFEALIQDESEEEKEEEEEKPVLKPAKPEK
NRINKAVAEEPPGLRNKKGKEEKSKGKAKNKPSATDSEGEDDEDMTKEKEPPRPGKDKDKKGAEQGSEEEKEEKEGEVKA
NDPYAHLSKKEKKKLKKQMDYERQVESLKAANAAENDFSVSQAEVSSRQAMLENASDIKLEKFSISAHGKELFVNADLYIV
AGRRYGLVGPNGKGKTTLLKHIANRALSIPPNIDVLLCEQEVVADETPAVQAVLRADTKRLRLLEEEKRLQGQLEQGDDTA
AEKLEKVYEELRATGAAAAEAKARRILAGLGFDPEMQNRPTQKFSGGWRMRVSLARALFMEPTLLMLDEPTNHLDLNAVI
WLNNYLQGWRKTLLIVSHDQGFLDDVCTDIIHLDTQRLHYYRGNYMTFKKMYQQKQKELLKQYEKQEKKLKELKAGGKS
TKQAEKQTKEVLTRKQQKCRRKNQDEESQDPPELLKRPREYTVRFTFPDPPPLSPPVLGLHGVTFGYEGQKPLFKNLDFGID
MDSRICIVGPNGVGKSTLLLLLTGKLTPTNGEMRKNHRLKIGFFNQQYAEQLHMEETPTEYLQRGFNLPYQDARKCLGRFGL
ESHAHTIQICKLSGGQKARVVFAELACREPDVLILDEPTNNLDIESIDALGEAINEYKGAVIVVSHDARLITETNCQLWVVEEQ
SVSQIDGDFDDYKREVLEALGEVMVNRPRD 
 
SDCCAG1 [serologically defined colon cancer antigen 1] Sequence Coverage: 3% 
MKTRFSTVDLRAVLAELNANLLGMRVNNVYDVDNKTYLIRLQKPDFKATLLLESGIRIYTTEFEWPKNMMPSSFAMKCRKH
LKSRRLVSAKQLGVDRIVDFQFGSDEAAYHLIIELYDRGNIVLTDYEYLILNILRFRTDEADDVKFAVRERYPIDHARAAEPLL
TLERLTEVIARAPRGELLKRVLNLLLPYGPALIEHCLIENGFSGNVKVDEKLESKDIEKILVCVQRAEDYLEKTANFNGKGYII
QKREVKPSLDANKPAEDILMYEEFHPFLFSQHLQCPYIEFESFDKEKQALKKLDNVXKDHENRLEALQQAQEIDKLKGELIE
MNLQIVDRAIQVVRSALANQIDWTEIGVIVKEAQAQGDHVASAIKELKLQTNHITMLLRNPYLLSEEEDGDGDGSIENSDAE
APKGKKKAKEQAAAEASEGQAAACRCGPQPVSLCQCQKVLXSXEVCCXKTTENCRSCXEGIQISREENKANLKRSTNSYFY
PKSKESVLVXEISVVYXFRELSHYRWSRSATEXDYCEKILNTRRHLCACXSSWSYQLCNXESNRRSHPSSDFDXSRHNGTLL
QRGLGCPCYHECLVGAPSSGIXNSTDRRVLNNWKLHDKRKKEFPSSFIPNDGVXLPFXGRXVLCLETSRXTKRQSAGXRHEN
IDKLHKXTHVRRNGTARRGRQQXRRDRGVMWNHGRSGTQDSGXSRGHCCSQWKRGTELXRWRSHQNSHERXRAHWXG
EGRGGRISXHHHXLVPSSVPKAPTETDSKRRIFXFKXQXITEPKTFVSQGEKRNEKEKAPMXLRGFRSDRRKGQRKRKCCAQ
XSXPEHKQKCGSWTANEKRPEEXNEKNEGKIQRPGXXRSXTYYEIVGICRFKQRRKGEERKERKNKRXTREKKPTETQRWT
AGFRCCXRNPVPSGVDSXLTRLCCGXATXXQGRTXSGSAGKXGKSIXLFDRATTSXRCTNVCYSNMCSLHHHDKLXIQSET
YSWSSEKGKSCKDSLEQFHALQRSNSKRKRLIPKCEGHRFTKKHSRESESVCPQSSARKKKI 
 
 
 
Figure 2.10:  Mass spectrometry peptide identifications (in red) for MeCP2 copurifying 
polypeptides from the QB2 pool of MeCP2. 
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Figure 2.11:  MeCP2 and Prpf3 precisely co-fractionation.  (A) The MonoQ 
fractionation of brain-derived nuclear extract reveals an overlap of Prpf3 and Mecp2 yet 
pools of each protein do not co-fractionate and remain independent of the other.  (B) Peak 
fractions of the QB1/2 fractionated over the MonoS resin show two distinct pools of 
MeCP2 peaking at 400 mM NaCl (QB1) and 550 mM NaCl (QB2) by western blot 
analysis.  Corresponding MonoS fractions probed for Prpf3 protein shows precise co-
fractionation with QB2 Mecp2.  
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Figure 2.12:  Co-IPs confirm that MeCP2 associates with Prpf3 in vivo. (A) Western 
blotting of a co-IP experiment from fractionated brain extract showing: a peak MeCP2 
fraction (lane 1, 5% input), IgG IP (lane 2), anti-MeCP2  IP (lane 3), and anti-MeCP2 IP 
treated with benzonase (lane 4), demonstrates that PRPF3 interacts with MeCP2 in brain 
independent of nucleic acids.  (B) Western blotting of a co-IP experiment from HA-
MeCP2 transfected HT22 cells showing:  whole cell extract (lane 1, 5% input), IgG IP 
(lane 2), anti-HA IP (lane 3) and anti-HA IP treated with benzonase (lane 4), 
demonstrates that PRPF3 interacts with MeCP2 cell culture independent of nucleic acids. 
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Figure 2.13:  HT22 hippocampal neuronal cells stably transected with HA-MeCP2, 
visualized by A. DAPI staining and B. indirect immunofluorescence for 
HA-MeCP2 with C. images merged, show HA-MeCP2 localizes to 
heterochromatic foci. 
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Figure 2.14:  MeCP2 directly interacts with Prpf3 and Sdccag1. For all experiments, the 
GST-tagged protein was bacterially generated and purified and the visualized [35S]-
methionine labeled interacting proteins were generated by in vitro transcription and 
translation. (A) Prpf3 (left) and Sdccag1 (middle) interact directly with GST tagged 
MeCP2 but not GST alone.  Eif2s3 (right) does not interact with either GST MeCP2 or 
GST Prpf3.  Benzonase treatment indicates these interactions are independent of nucleic 
acids.  (B) Reciprocally, MeCP2 interacts with GST tagged Prpf3 independent of nucleic 
acids.   
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Figure 2.15:  (A) GST-MeCP2 deletion constructs mapped the region of MeCP2 
required for the direct interactions with Prpf3 or Sdccag1 in vitro.  (B) GST tagged 
MeCP2 containing the indicated RTT nonsense mutations disrupt Prpf3 binding if 
truncations are prior to amino acid 104, but identify a second Prpf3 binding site on 
MeCP2 in the MBD between amino acids 104 and 141.  All RTT truncations tested 
abolished Sdccag1 binding to MeCP2. (C) GST tagged MeCP2 containing the indicated 
RTT mutations residing outside of the Prpf3 interaction domains maintain the interaction 
with Prpf3. (D) Map of MeCP2e2 protein showing the Prpf3 and Sdccag1 interaction 
domains with boundary amino acid numbers.  The MBD, TRD, and (*) RNA binding 
domain are indicated. 
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Figure 2.16:  Coomassie brilliant blue stained SDS-PAGE gels from GST pull-down 
experiments.  Staining shows equivalent levels of GST-fusion proteins in each pull-down 
reaction. A. GST-fusion proteins from Figure 2.15A top, Prpf3. B. GST-fusion proteins 
from Figure 2.15A bottom, Sdccag1. C. GST-fusion proteins from Figure 2.15B top, 
Prpf3. D. GST-fusion proteins from Figure 2.15B bottom, Sdccag1. 
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Figure 2.17:  The MeCP2-Prpf3 complex interacts with mRNA in vivo.  (A) RT-PCR 
analysis of a RIP from HA-MeCP2 stably transfected HT-22 cells indicates an 
association of HA-MeCP2 with Cdk10 mRNA (top, lane 2), but not Casc3 (bottom, lane 
2). Control RIPs using normal rabbit serum (IgG) (top and bottom, lane 3) show no RT-
PCR product.  RT-PCRs of unbound RNA from RIPs indicate target mRNAs were 
present in all RIP samples (lanes 4 and 5).  All RT-PCRs were RNase sensitive (+ 
RNase) confirming RNA and not DNA as being assayed.  (B) An anti-HA RIP followed 
by anti-Prpf3 Re-RIP experiment from HA-MeCP2 HT-22 cells was assayed for Cdk10 
mRNA by RT-PCR (lane 2).  Control RIP and ReRIP experiments using normal rabbit 
serum (IgG) showed no product by RT-PCR (lane 3).  Unbound mRNA was assayed by 
RT-PCR for the RIP (lanes 6 and 7) and reRIPs (lanes 4 and 5) to confirm the presence of 
the Cdk10 mRNA in the reactions.  All RT-PCRs were sensitive to RNase treatment 
(lower panel) confirming the amplifications were from RNA and not DNA templates.  
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Figure 2.18:  Xenopus lampbrush chromosomal distribution of hMeCP2.  Transcripts 
coding for hMeCP2-HA were injected into stage IV oocytes and nuclear spreads were 
prepared.  Endogenous xNF7 (red) stains actively transcribed DNA, including a highly 
extended chromatin loop (white arrow).  MeCP2 (green) is detected extensively on 
heterochromatin rich chromosomal axes, as well as on transcriptionally active loops 
(white arrow).  Insets show a close up of an isolated loop with MeCP2 staining and 
merge with xNF7.  Scale bar represents 5 μm. 
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Figure 2.19:  Xenopus lampbrush chromosome showing anti-HA staining pattern of 
uninjected controls.  A phase contrast image and DAPI staining (red) show lampbrush 
chromosome axis and loops, while anti-HA staining (green) shows there is no detectable 
signal on chromatin of uninjected oocytes.  Scale bar represents 5 μm.     
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Table 1:  PCR and RT-PCR oligonucleotide primers 
 
 
 
Primer Plasmid Construct  Sequence (5’-3’)       
1 pGEM ratAbcf1   ATGCCGAAGGGTCCCAAGCAGC 
2 pGEM ratAbcf1   TCAATCCCGAGGTCGGTTGAC 
3 pGEM ratEif2s1   ATGCCGGGTCTAAGTTGTAGATTTTATCAAC 
4 pGEM ratEif2s1   TTAATCTTCAGCTTTGGCTTCCATTTCTTCTG 
5 pGEM ratEif2s2   ATGTCCGGGGACGAGATGATTTTTGATCCTAC 
6 pGEM ratEif2s2   TTAGTTAGCTTTGGCACGGAGCTG 
7 pGEM ratEif2s3   ATGGCTGGGGGTGAGGCTG 
8 pGEM ratEif2s3   TCAGTCATCATCTACAGTCGGCTTAATG 
9 pGEM ratMeCP2  ATGGTAGCTGGGATGTTAGGGC 
10 pGEM ratMeCP2  TCAGCTAACTCTCTCGGTCACG 
11 pGEM ratPrpf3   ATGGCACTGTCTAAGCGGGAACTGGATG 
12 pGEM ratPrpf3   CTACAGAGAACATGGCGCGTGA 
13 pGEM ratSdccag1  ATGAAGACCCGCTTCAGCACTGTTGAC 
14 pGEM ratSdccag1  CTATTTTCTTTTTACGTGCAGAAGATTGGG 
15 pGEM human Prpf3  ATGGCACTGTCAAAGAGGGAGC 
16 pGEM human Prpf3  TCAATCAGTGGACTCTAAC 
17 pCDNA3.1 ratAbcf1  GCGGCCGCATGCCGAAGGGTCC 
18 pCDNA3.1 ratAbcf1  CGCTCGAGTCAATCCCGAGGTCGG 
19 pCDNA3.1 ratEif2s1  GCGGCCGCATGCCGGGTCTAAG 
20 pCDNA3.1 ratEif2s1  CGCTCGAGTTAATCTTCAGCTTTGGCTTC 
21 pCDNA3.1 ratEif2s2  GCGGCCGCATGTCCGGGGAC 
22 pCDNA3.1 ratEif2s2  CGCTCGAGTTAGTTAGCTTTGGCACG 
23 pCDNA3.1 ratEif2s3  GCGGCCGCATGGCTGGGGGTG 
24 pCDNA3.1 ratEif2s3  CGCTCGAGTCAGTCATCATCTACAGTCG 
25 pCDNA3.1 ratMeCP2  GCGGCCGCATGGTAGCTGGGATG 
26 pCDNA3.1 ratMeCP2  CGCTCGAGTCAGCTAACTCTCTCGGTC 
27 pCDNA3.1HA humanMeCP2 GCGGCCGCATGGTAGCTGGGATG  
28  pCNA3.1HA humanMeCP2 CGCTCGAGTCAGCTAACTCTCTCGGTC 
29 pCDNA3.1 ratPrpf3  GCGGCCGCATGGCACTGTCTAAGC 
30 pCDNA3.1 ratPrpf3  CGCTCGAGTCACGCGCCATGTTCTC 
31 pCDNA3.1 ratSdccag1  GCGGCCGCATGAAGAGCCGCT 
32 pCDNA3.1 ratSdccag1  CGCTCGAGCTATTTCCTTTTTACGTTCAGAAG 
33 pCDNA3.1 humanPrpf3  AGAATTCATGGCACTGTCAAAGAG 
34 pCDNA3.1 humanPrpf3  CTCGAGTCAATCAGTGGACTCTAAC 
35 pGEX5X ratPrpf3  AGAATTCATGGCACTGTCTAAGC 
36 pGEX5X ratPrpf3  CTCGAGTCACGCGCCATGTTCTC 
37 pGEX5X MeCP2 d1  AGAATTCGCCTCCCCCAAACAG 
38 pGEX5X MeCP2 d1  CTCGAGTCAGCTAACTCTCTCGG 
39 pGEX5X MeCP2 d2  AGAATTCAAGCAAAGGAAATCTGGC  
40 pGEX5X MeCP2 d2   CTCGAGTCAGCTAACTCTCTCGG 
41 pGEX5X MeCP2 d3  AGAATTCGGCACCACGAGACC 
42 pGEX5X MeCP2 d3  CTCGAGTCAGCTAACTCTCTCGG  
43 pGEX5X MeCP2 d4  AGAATTCACGGTCAGCATCGAG 
44 pGEX5X MeCP2 d4  CTCGAGTCAGCTAACTCTCTCGG 
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(Table 1 continued) 
 
 
 
45 pGEX5X MeCP2 d5  AGAATTCATGGTAGCTGGGATGTTAG 
46 pGEX5X MeCP2 d5  CTCGAGGGTCTTGCGCTTCTTG 
47 pGEX5X MeCP2 d6  AGAATTCGGCACCACGAGACC 
48 pGEX5X MeCP2 d6  CTCGAGACCGAGGGTGGACAC   
49 RT-PCR mouseFRG1 5’  AATTGCCCTGAAGTCTGGCTATGG 
50 RT-PCR mouseFRG1 3’  CTTTCAATTTGGCTCTCCTGTCCAG 
51 RT-PCR mouseCDK10 5’ GGCCAGGGATACCCAGACAG 
52 RT-PCR mouseCDK10 3’ CCTCCGAGAAGGGTGTTGGC 
53 RT-PCR mouseCASC3 5’ GATCCTCATCGTCATCCAAGTGC 
54 RT-PCR mouseCASC3 5’ CTACAGTGAAGAGGAGAATTCCAAGGTG 
55 pGEX5X MeCP2 S49X  AGAATTCGCCTCCCCCAAACAG 
56 pGEX5X MeCP2 S49X  ACTCGAGTCATGGCTGCACGGGC 
57 pGEX5X MeCP2 S68X  AGAATTCGCCTCCCCCAAACAG 
58 pGEX5X MeCP2 S68X  ACTCGAGTCACCCTTCTGATGTCTC 
59 pGEX5X MeCP2 W104X AGAATTCGCCTCCCCCAAACAG 
60 pGEX5X MeCP2 W104X ACTCGAGTCAGCCTTCAGGCAGG 
61 pGEX5X MeCP2 Y141X AGAATTCGCCTCCCCCAAACAG 
62 pGEX5X MeCP2 Y141X ACTCGAGTCACGCAATCAACTCC 
63 pGEX5X MeCP2 R168X  AGAATTCGCCTCCCCCAAACAG 
64 pGEX5X MeCP2 R168X  ACTCGAGTCATCATCTCGCCGGGAGGG 
65 pGEX5X MeCP2 S204X  AGAATTCGCCTCCCCCAAACAG 
66 pGEX5X MeCP2 S204X  CTCGAGTCACGTGGCCGCCTTG 
67 pGEX5X MeCP2 R106W AGAATTCATGGTAGCTGGGATGTTAGGG 
68 pGEX5X MeCP2 R106W CTCGAGTCAGCTAACTCTCTCGGTC 
69 pGEX5X MeCP2 F155S  AGAATTCATGGTAGCTGGGATGTTAGGG 
70 pGEX5X MeCP2 F155S   CTCGAGTCAGCTAACTCTCTCGGTC 
71 pGEX5X MeCP2 R294X  AGAATTCATGGTAGCTGGGATGTTAGGG 
72 pGEX5X MeCP2 R294X  CTCGAGTCATCGGATAGAAGACTCCTTC 
73 pGEX5X MeCP2 F155S/R294X  AGAATTCATGGTAGCTGGGATGTTAGGG 
74 pGEX5X MeCP2 F155S/R294X  CTCGAGTCATCGGATAGAAGACTCCTTC 
75 pGEX5X MeCP2 H370X AGAATTCATGGTAGCTGGGATGTTAGGG 
76 pGEX5X MeCP2 H370X  CTCGAGTCAGTGATGGTGGTGGTGC 
77 pGEX5X MeCP2 E397X  AGAATTCATGGTAGCTGGGATGTTAGGG  
78 pGEX5X MeCP2 E397X  CTCGAGTCACTCGGAGCTCTCGG 
79 pGEX5X MeCP2 R453X  AGAATTCATGGTAGCTGGGATGTTAGGG 
80 pGEX5X MeCP2 R453X  CTCGAGTCATCGGTGTTTGTACTTTTCTG 
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CHAPTER 3 
INSIGHTS INTO THE MOLECULAR FUNCTION OF MECP2 AND RETT 
SYNDROME 
 
 
 
CONCLUSIONS 
 
 
 
In the past two decades we have witnessed an evolving role for MeCP2 function.  
MeCP2 was originally identified by its ability to bind methylated DNA and is the 
founding member of the methyl-CpG-binding domain (MBD) family of proteins 
(Hendrich and Bird, 1998; Meehan et al., 1992).  The proteins first biological function 
was repressing transcription by binding methylated DNA and recruiting transcriptional 
co-repressor complexs (Jones et al., 1998; Nan et al., 1997; Nan et al., 1998).  In 1999 a 
genetic link between MeCP2 and Rett Syndrome (RTT) was identified (Amir et al., 
1999).  RTT is a severe postnatal neurodevelopmental disorder (Rett, 1966), 
characterized by a period of apparently normal development from birth to 6-18 months 
followed by a regression of obtained language and motor skills (Chahrour and Zoghbi, 
2007).  This severe disorder usually exhibits a deceleration of head growth, respiratory 
dysfunction, scoliosis, cognitive impairment, seizures, and social withdraw in patients 
(Hagberg et al., 1983; Rett, 1966).  In addition to RTT, numerous MECP2 mutations 
have now been linked to a variety of other disorders, including autism, Angelman 
syndrome, learning disabilities, and mental retardation syndromes (Carney et al., 2003; 
Chahrour and Zoghbi, 2007; Christodoulou and Weaving, 2003; Lam et al., 2000; 
Watson et al., 2001; Ylisaukko-Oja et al., 2005; Zoghbi, 2005).  The initial connection of 
MeCP2 to RTT is responsible for a large push among the research community to 
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understand the biology of MeCP2.  Despite an early focus on gene specific repression, 
more recent work has expanded MePC2’s regulatory role beyond transcriptional 
repression; MeCP2 is implicated in transcriptional activation, genome-wide 
transcriptional silencing, mediating chromatin and nuclear architecture, and regulating 
pre-mRNA splicing as well (Chadwick and Wade, 2007; Chahrour et al., 2008; Skene et 
al.; Yasui et al., 2007; Young et al., 2005).  
The identity of MeCP2 as a multifunctional protein is a result of using a variety of 
techniques from numerous cellular contexts, however only the biochemical 
characteristics of the endogenous MeCP2 protein in the brain are relevant to RTT.  Many 
important protein-protein interactions have been identified by biochemical co-purification,  
notably, the first biological function for MeCP2 as a transcriptional repressor was 
established by biochemical purification of a MeCP2 complex containing Sin3A-HDAC 
from Xenopus oocytes (Jones et al., 1998).  Despite a large body of work suggesting 
MeCP2 interacts with many partners, the only published attempt to purify native MeCP2 
complexes from mammalian brain resulted in a conclusion that MeCP2 purifies in a 
single biochemical pool that does not stably associate with other proteins (including 
itself) (Klose and Bird, 2004).   
From work described in Chapter 2, we begin to reveal molecular mechanisms of 
MeCP2 function relevant to RTT through the identification of multiple distinct brain-
derived MeCP2 protein pools, agreeing with the structural and functional data proposing 
multiple roles for MeCP2 (Hite et al., 2009).  A previous study indicates no brain derived 
MeCP2 protein interacts with MonoQ strong anion resin (Klose and Bird, 2004).  This is 
a reasonable outcome for a basic protein (pI=10) unassociated with other factors.  We 
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have confirmed that brain derived MeCP2 which is unable to bind the MonoQ (QF) is 
unassociated with other proteins.  Recent in vitro work shows MeCP2 can form DNA-
MeCP2-DNA bridges, as well as directly compact chromatin without DNA methylation, 
ATP, or other proteins (Georgel et al., 2003; Nikitina et al., 2007).  What's more, a large 
portion of MeCP2 is observed at pericentric heterochromatin (Nan et al., 1993), and 
MeCP2 has been shown to consolidate chromocenters during cellular differentiation 
(Brero et al., 2005).  Aside from extraction disrupted complex MeCP2, it is possible brain 
derived MeCP2 purified in the QF pool functions as a monomer in nuclear architecture.   
In our lab, a distinguishing characteristic over other labs results is that we observe 
distinct pools of MeCP2 with differential anion resin affinities present in mammalian 
brain extracts.  Furthermore, we found this interaction is not due to MeCP2 
phosphorylation or nucleic acid mediated binding, suggesting the QB MeCP2 association 
is from negatively charged protein partners facilitating the interactions.  We have further 
characterize one biochemically distinct pool of MeCP2  that is found to co-fractionate 
with Prpf3, a known spliceosome-associated protein (Wang et al., 1997), Sdccag1 
(Scanlan et al., 1998), a mediator of nuclear export (Bi et al., 2005), ATP-binding 
cassette 50, and 3 components of a translation initiation complex (Eif2 subunits 1, 2, and 
3).  We find MeCP2 specifically interacts with Prpf3 and Sdccag1, but not other 
copurifying candidates. 
MeCP2’s association with Prpf3, a major component of the spliceosome, supports 
MeCP2 as having a role in modulating mRNA splicing; exactly what that role might be is 
still not clear.  Interestingly, a recent study suggests that differential gene body 
methylation may play a role in transcript splicing (Laurent et al.).  By identifying the 
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genome wide methylation status in multiple human cell types, the group found that exons 
were more highly methylated than introns, and that there were sharp transitions of 
methylation at exon-intron boundaries (Laurent et al.).  Based on what is known about 
MeCP2 and Prpf3 independently, potentially MeCP2’s direct interaction with Prpf3 could 
function in splice site selection.  Prpf3 is one of multiple associated proteins of the 
U4/U6.U5 tri-snRNP complex that is recruited to the splice site to form and stabilize the 
functional spliceosome, and is essential for pre-mRNA splicing (Brown and Beggs, 1992; 
Horowitz et al., 1997; Lauber et al., 1997; Wang et al., 1997). Importantly, MeCP2 can 
bind RNA directly (Jeffery and Nakielny, 2004), and has been implicated as a regulator 
of alternative splicing in the HeLa and Neuro2A cell lines through an RNA-dependent 
interaction with YB-1 (Young et al., 2005), a protein known to participate in splicing of 
mRNAs (Philips et al., 1998; Stickeler et al., 2001).  While we were unable to detect YB-
1 as a component of the MeCP2/Prpf3/Sdccag1 complex in brain, it is inefficient to 
inhibit the highly active and stable RNases that would abolish any YB-1/RNA/MeCP2 
interaction during purification so we cannot rule out that YB-1 could be part of a larger 
RNA-dependent alternative splicing complex.  Nevertheless, a direct interaction of 
MeCP2 and Prpf3 further supports a role for MeCP2 in mRNA splicing regulation. 
MeCP2 is present at the promoter of many actively transcribed genes (Yasui et al., 
2007), and activates a majority of genes it regulates in the mouse hippocampus (Chahrour 
et al., 2008).  MeCP2’s ability to bind chromatin in vivo appears to be dynamically 
regulated by phosphorylation in the brain (Chen et al., 2003; Tao et al., 2009).  
Experimentally, MeCP2 is known to bind RNA in vitro with a similar affinity as to 
methylated DNA and that the two activities are mutually exclusive (Jeffery and Nakielny, 
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2004).  Thus, MeCP2 at an active promoter or within the body of a transcribed gene 
would be well positioned spatially upon its release to interact with the transcripts of the 
genes it activates and influence splice site selection.  Therefore, it is reasonable to 
propose that MeCP2 activated genes would also be targets for splicing regulation by a 
MeCP2 containing complex.  Supporting this model, RNA transcripts from Cdk10, a 
gene positively regulated by MeCP2 binding at its promoter (Chahrour et al., 2008) and 
abnormally spliced in Mecp2308/Y mice (Young et al., 2005), were associated with both 
MeCP2 and Prpf3 in vivo. 
Sdccag1 was originally identified from colon cancer patients by a serological 
analysis of recombinant cDNA expression libraries (SEREX) (Scanlan et al., 1998) and 
later identified as a tumor suppressor by its ability to cause cell cycle arrest in a non-
small-cell lung cancer cell line (Carbonnelle et al., 2001).  The significance of finding 
Sdccag1 as part of the MeCP2-Prpf3 complex can only be implied due to the limited 
information on its function in vertebrates and Drosophila.  Bioinformatically the Sdccag1 
protein contains a predicted RNA-binding domain homologous to a eukaryotic small 
nuclear ribonucleoprotein (Marchler-Bauer et al., 2009), suggesting the capacity to 
function in mRNA splicing.  Functionally, the Drosophila Sdccag1 homolog Caliban, has 
been shown to interact with and mediate the nuclear export of the Prospero homeodomain 
transcription factor (Prox in mammals) and this interaction and function is conserved in 
mammalian cells (Bi et al., 2005).  Notably, Mecp2308/Y mice, which produce a truncated 
form of MeCP2 and reproduce many of the classical features of RTT (Moretti et al., 
2005; Shahbazian et al., 2002), have been shown to have multiple genes that are 
abnormally spliced in the brain (Young et al., 2005).  This suggests the C-terminal 
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portion of MeCP2, which we have identified as the putative Sdccag1 interaction domain, 
plays a critical role in regulating alternative splicing. 
It is tempting to speculate that the MeCP2/Prpf3/Sdccag1 complex may not only 
be involved in splicing mRNA, but also transporting mRNAs to the cytoplasm for 
translation. Consistent with this model, MeCP2 has been shown to have both a nuclear 
and cytoplasmic localization in neuronal cell lines (Miyake and Nagai, 2007).  This idea 
raises the possibility that other co-purifying proteins identified may indeed be part of the 
MeCP2 complex.  ABC50 has been shown to interact with the Eif2 complex (Tyzack et 
al., 2000), and Eif2 is known to play an important role in the regulation of translation 
initiation (Pain, 1996; Price et al., 1994).  Although MeCP2 or Prpf3 did not directly 
interact with any of these proteins in our study, an untested Sdccag1 could function as a 
scaffolding protein, linking all of the identified proteins.  Theoretically, this would result 
in a complex that could function in mRNA splicing, export of RNA to the cytoplasm, and 
ultimately translation regulation.     
  Structural studies indicate that MeCP2 contains at least six structurally distinct 
domains (Adams et al., 2007).  Mutations generally manifested as point mutations 
resulting in a single missense or nonsense amino acid change have been identified in all 
domains of MECP2 from RTT patients, suggesting that all domains are critical for 
MeCP2 function (Hite et al., 2009; Moore et al., 2005).  Although all these mutations 
produce clinical RTT pathology, certain mutations are more strongly associated with 
particular symptoms and disease severity suggesting that all RTT mutations in MECP2 
are not equal, with some potentially being more disruptive towards MeCP2’s many 
functions (Jian et al., 2005; Neul et al., 2008).  Considering the range of mutations 
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throughout MECP2 in RTT, it is not surprising that many RTT mutations are within, or 
predicted to affect both the Prpf3 and Sdccag1 binding domains, disrupting the 
MeCP2/Prpf3/Sdccag1 complex and presumably MeCP2-mediated splicing regulation 
and mRNA transport.  
Current literature suggests many roles for MeCP2.  A hypothetical model using 
information available easily allows for integration of a MeCP2/Prpf3/Sdccag1 complex 
into suspected roles of MeCP2 (Figure 3.1).  In this model, MeCP2 is associated with 
transcriptionally active promoters (Chahrour et al., 2008; Yasui et al., 2007), and at some 
targets, activation is dependent on neuronal stimulation leading to subsequent 
phosphorylation of MeCP2 (Chen et al., 2003; Martinowich et al., 2003; Zhou et al., 
2006).  Phosphorylation results in release of MeCP2 from target promoters (Chen et al., 
2003; Zhou et al., 2006) strategically localizing the protein spatially and temporally to 
interact with mRNA (Jeffery and Nakielny, 2004).  Phosphorylation of MeCP2 and 
interaction with mRNA prevents MeCP2 from rebinding methylated chromatin (Chen et 
al., 2003; Jeffery and Nakielny, 2004) and could allow for recruitment of splicing factors 
such as Prpf3, Sdccag1 and other spliceosomal components to modulate splicing (Young 
et al., 2005).  Interaction of a MeCP2/Prpf3/Sdccag1 complex with mRNA could also 
later function in mRNA transport to the cytoplasm, a known destination of MeCP2 in 
neurons (Miyake and Nagai, 2007), and possibly target ribosomes for translation.              
With MeCP2 continuing to emerge as a multifunctional protein and its biological 
role in RTT unclear, identifying biochemically distinct pools of Mecp2 in the brain 
containing novel MeCP2 interacting proteins is a valuable tool towards an understanding 
MeCP2 function and its dysfunction in RTT.  Work in Chapter 2 shows there are at least 
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four distinct pools of MeCP2 in mammalian brain.  Interestingly, data suggests MeCP2 
has the capacity to function in four ways:  repression, activation, nuclear structure, and 
mRNA splicing.  We have characterized two biochemically distinct pools of MeCP2, one 
confirming MeCP2 present as a monomer (possibly involved in nuclear structure), and 
another in a novel punitive mRNA splicing complex.  The complexity of RTT likely 
stems from perturbation of multiple MeCP2 functions.  However, these results add to the 
mounting evidence indicating that one such critical function of MeCP2 in the brain 
involves RNA biogenesis, and adds to a growing list of possible mechanisms perturbed in 
RTT.   
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FIGURES 
 
 
 
 
Figure 3.1:  Model for the brain derived MeCP2 mRNA splicing complex.  A)  Neuronal 
depolarization results in transcriptional activation and subsequent MeCP2 
phosphorylation.  B)  A MeCP2 containing splicing complex interacts with nascent 
mRNA.  C)  Sdccag1 mediated export of MeCP2 containing mRNA complex.    
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APPENDIX A* 
 
DEVELOPMENTAL CONTROL OF DNA METHYLATION MEDIATED 
SILENCING 
 
 
*Data is included in a manuscript by Gert Jan Veenstra, (in preparation).  
 
 
 
INTRODUCTION 
 
Many genes and a majority of non-protein coding DNA in a eukaryotic genome is 
silenced in any particular cell during the organism’s life (Elgin and Grewal, 2003).  
Transcriptional silencing is associated with the formation of heterochromatic domains 
and is influenced by covalent modifications of chromatin components.  These 
modifications are essential for normal development and can be re-established after each 
cell division to maintain the stability of the genome (Bird, 2002; Jenuwein and Allis, 
2001; Kouzarides, 2002; Turner, 2000).  DNA methylation in the vertebrate genome is 
one such epigenetic mark generally associated with heterochromatic silencing. 
DNA Methylation in vertebrates is characterized by the post-replication addition 
of a methyl group to the 5 carbon of cytosine (5mC) resulting in symmetrically 
methylated CpG dinucleotides carried out by a member of the DNA methylatransferase 
(DNMT) family of proteins.  Family members catalyze the transfer of a methyl-group 
from S-adenosyl methionine (SAM) to the C5 position of cytosine.   
DNA methylation in mammials is established on the genome through a sequence of 
developmental events (Razin and Shemer, 1995).  Pre-implantation mouse embryos 
undergo a global demethylation event followed by de novo methylation by DNA 
methyltransferase 3A (DNMT3A) and DNMT3B, which is critical in determining 
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somatic DNA methylation patterns (Hsieh, 1999; Jaenisch et al., 1982; Okano et al., 
1998; Okano et al., 1999).  After initial methylation patterns are established, they are 
maintained between cell generations by the maintenance methyltransferase DNMT1 
(Bestor et al., 1988; Leonhardt et al., 1992).   
Studies suggest DNA methylation is important in establishing and maintaining 
heterochromatic structures for gene regulation (Eden et al., 2003; Gaudet et al., 2003).  
Transient transfection and in vitro transcription assays consistently demonstrate that the 
repression of transcription is dependent on DNA methylation (Levine et al., 1993; 
Murray and Grosveld, 1987).  However, by comparing transcription rates of methylated 
and unmethylated stably integrated transgenes during Xenopus embryo development, we 
have evidence suggesting the repressive nature of DNA methylation may be 
developmentally controlled.     
 
RESULTS 
 
To determine the effects of DNA methylation on transcription during 
development of a vertebrate, the plasmid pGL3-CMV, containing a CMV promoter 
driving a luciferase gene, were differentially methylated in vitro with the bacterial 
methylase M.Sss I.  Methylation status of the plasmids was tested by methyl-sensitive 
restriction digestion using BstUI after linearization (Figure A.1).  Unmethylated plasmids 
are cleaved into several pieces, while methylated plasmid is comparable to the linear 
control, indicating it is fully methylated and not able to be cut by BstUI (Figure A.1).  
Linearized plasmids were subsequently used for Xenopus transgenesis. 
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The model organism Xenopus laevis allows for exogenous DNA to be stably 
incorporated into its genome (Amaya and Kroll, 1999).  Transgenic Xenopus were 
produced with either methylated or unmethylated pGL3-CMV, and embryos developing 
normally were collected at:  stages 9 (n = 45), stage 11 (n = 45), stage 15 (n = 28), or 
stage 21 (n = 20).  RNA and DNA were purified from the various stages of unmethylated 
and methylated pGL3-CMV transgenic embryos and relative transcript levels were 
determined by reverse transcription quantitative PCR (RT-qPCR), normalized to 
integrated plasmid DNA.  Stage 9 and 11 methylated pGL3-CMV embryos show 
substantial levels of active transcription compared, although lower than unmethylated 
pGL3-CMV embryos (Figure A.2).  By stage 15, methylated pGL3-CMV embryos show 
a large drop in transcription compared to unmethylated pGL3-CMV embryos, and by 
stage 21 methylated pGL3-CMV transcript levels do not reach threshold, indicating it is 
strongly repressed (Figure A.2).  We conclude DNA methylation associated repression of 
stably integrated plasmids is developmentally regulated.           
          
DISCUSSION 
 
 The most common modification of vertebrate genomes, DNA methylation, is 
primarily associated with transcriptional repression (Ballestar and Wolffe, 2001).  Global 
levels of DNA methylation vary not only between species, but different stages of 
embryonic development for some.  In mice, embryos undergo global (but not total) 
demethylation before implantation, followed by de novo methylation to establish somatic 
DNA methylation patterns, possibly re-programming epigenetic mediated repression  
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(Hsieh, 1999; Jaenisch et al., 1982; Okano et al., 1998; Okano et al., 1999).  However, in 
Xenopus there is no genome-wide demethylation and re-methylation event (Veenstra and 
Wolffe, 2001).  Oddly, genes with heavily methylated promoters have been found to be 
actively transcribed early in Xenopus embryo development, (Gert Jan Veenstra – personal 
communication).  Initial studies suggest DNA methylation is important in establishing 
and maintaining heterochromatic structures for gene regulation (Eden et al., 2003; 
Gaudet et al., 2003).  Mammalian cell culture experiments utilizing transient transfection 
and in vitro transcription assays consistently show repression of transcription is 
dependent on DNA methylation (Levine et al., 1993; Murray and Grosveld, 1987).  Also, 
before transcriptional senescence of mature eggs, Xenopus oocytes are able to strongly 
repress methylated plasmids (Kass et al., 1997).  Furthermore, depletion of DNA 
methyltransferases lead to premature onset of embryonic gene transcription in Xenopus 
embryos, indicating DNA methylation can be repressive during early development 
(Stancheva and Meehan, 2000).  This raises questions as to why some heavily methylated 
promoters are observed active early in Xenopus embryo development.  Is it merely due to 
unmethylated copies of the tetraploid Xenopus genome, or associated with 
developmentally regulated factors? 
 We have investigated the transcriptional activity of methylated versus 
unmethylated plasmid constructs stably integrated in developing Xenopus embryos.  
Completely methylated plasmids injected into Xenopus oocytes are strongly repressed 
after “chromatization” has taken place on the transient DNA molecules (Kass et al., 
1997).  The Xenopus transgenesis procedure allows for exogenous DNA to be stably 
incorporated into the genome (Amaya and Kroll, 1999).  Upon fertilization and 
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subsequent cell divisions, integrated transgenes likely contain the normal complement of 
chromatin factors found elsewhere in the genome.  It is reasonable to think that transgene 
DNA methylated in vitro and subsequently integrated into the genome would be potently 
repressed as it is the case for injected plasmids.  However, we find here that DNA 
methylation does not strongly silence transcription of the CMV promoter during early 
embryogenesis (stages 9 - 11), and we do not see complete transgene repression until 
neural tube formation begins (stages 15 – 21).  This would suggest that although DNA 
methylation marks are present, the repressive effect associated is developmentally 
regulated.  Xenopus does not have genomic imprinting and does not have genome wide 
demethylation events during development (Veenstra and Wolffe, 2001).  This could 
suggest that genome wide demethylation events observed in mammals are strictly 
imprinting related.  The complete role of DNA methylation remains a mystery, however, 
in time continuing research will help further understanding the complex nature of 
epigenetics and its related diseases.     
 
MATERIALS AND METHODS 
 
Plasmid constructs and in vitro methylation 
 
CMV promoter of pEGFP (Clontech) was PCR amplified using primers: 5’-
GGTACCTAGTTATTAATAGTAATCAATTAC-3’ 5’-
CTCGAGGTGGCGACCGGTAGCGCTAGCGGA-3’, cloned into pGEM T-Easy 
(Promega), sequenced and cloned into KpnI and XhoI of pGL3 (Promega).  Methyl 
pGL3-CMV was methylated in vitro with the bacterial methylase M.Sss I (New England 
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Biolabs) by adding 160 µM S-Adenosyl methionine (SAM) and 1U M.Sss I/µg plasmid 
and incubating for 1 hour at 37°C, followed by a second addition of M.Sss I and SAM 
and additional 1 hour at 37°C.  Plasmid methylation status is tested by methyl-sensitive 
restriction digest using with 20U BstUI/µg linear pGL3-CMV for 1 hour at 60°C.  
 
Generation of Xenopus transgenics 
Procedure utilizing Xenopus laevis were purchased from Xenopus Express, Inc. 
and carried out in accordance with established UIUC IACUC approved protocols for 
animal welfare. Xenopus transgenesis was carried out essentially as described (Kroll and 
Amaya, 1996, Development 122(10):3173–3183), however, the sperm nuclei were not 
digested with restriction enzymes. Briefly, Xenopus high-speed egg extract (EXT) and 
sperm head nuclei were purified, and stored at −80°C in aliquots until use. The pGL3-
CMV plasmid or methyl pGL3-CMV was linearized with Alw NI, purified, and 
incubated along with linear pEGFP-N1(100 ng each per experiment) and sperm nuclei for 
5 min. EXT (10 μl) and 20 μl Sperm dilution buffer (SDB = 250 mM sucrose, 75 mM 
KCl, 0.5 mM spermidine, 0.2 mM spermine) were mixed and incubated at 65°C for 
5 min, then centrifuged at 16,000 × g for 3 min to remove precipitate. The soluble 
fraction (6 μl) was diluted to 22 μl with SDB plus 10 mM MgCl2. This activating solution 
was added to the nuclei/sperm mix and incubated for 15 min at room temperature. The 
swollen nuclei (with integrated transgenes) were gently added to 170 μl SDB and used 
for micro-injection at a rate of 0.586 μl/min using a microliter syringe pump (Harvard 
Apparatus).  Normally developing embryos were collected at various stages, scored for 
percent transgenic by EGFP fluorecence and frozen in Trizol reagent (Invitrogen).   
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Quantitative reverse transcription PCR (qRT-PCR) 
For each sample, total RNA and genomic DNA were purified from embryos using 
Trizol reagent per manufacture’s protocol.  RNA was then treated with 1U RQ1 DNase 
(Promega) per 1ug RNA for 30 min. at 37°C.  cDNA synthesis was preformed using 1ug 
of total RNA, 50ng of random hexamer, and Superscript III (Invitrogen) per 
manufacture’s suggested method.  Relative transcript levels of integrated methylated 
pGL3-CMV luciferase to unmethylated pGL3-CMV luciferase construct was determined 
using 1ul of (1:20 diluted) cDNA (in triplicate), iQ SYBR Supermix, and luciferase 
transgene specific primers (5’-GAATCCATCTTGCTCCAACAC-3’ and 5’- 
TTCGTCCACAAACACAACTC-3’) on a Bio-Rad iCycler IQ machine.  Relative 
transcript levels were normalized to integrated transgene copy number in genomic DNA.  
Experiments were preformed at least 3 times.  Data analyses were preformed using the 
comparative Ct method and error bars are + standard error of the mean. 
 
 
 
 
 
 
 
 
 
 
 107
REFERENCES 
 
Amaya, E., and Kroll, K.L. (1999) A method for generating transgenic frog embryos. 
Methods Mol Biol 97: 393-414. 
 
Ballestar, E., and Wolffe, A.P. (2001) Methyl-CpG-binding proteins. Targeting specific 
gene repression. Eur J Biochem 268: 1-6. 
 
Bestor, T., Laudano, A., Mattaliano, R., and Ingram, V. (1988) Cloning and sequencing 
of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-
terminal domain of the mammalian enzymes is related to bacterial restriction 
methyltransferases. J Mol Biol 203: 971-983. 
 
Bird, A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21. 
 
Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003) Chromosomal instability 
and tumors promoted by DNA hypomethylation. Science 300: 455. 
 
Elgin, S.C., and Grewal, S.I. (2003) Heterochromatin: silence is golden. Curr Biol 13: 
R895-898. 
 
Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., 
Leonhardt, H., and Jaenisch, R. (2003) Induction of tumors in mice by genomic 
hypomethylation. Science 300: 489-492. 
 
Hsieh, C.L. (1999) In vivo activity of murine de novo methyltransferases, Dnmt3a and 
Dnmt3b. Mol Cell Biol 19: 8211-8218. 
 
Jaenisch, R., Harbers, K., Jahner, D., Stewart, C., and Stuhlmann, H. (1982) DNA 
methylation, retroviruses, and embryogenesis. J Cell Biochem 20: 331-336. 
 
Jenuwein, T., and Allis, C.D. (2001) Translating the histone code. Science 293: 1074-
1080. 
 
Kass, S.U., Landsberger, N., and Wolffe, A.P. (1997) DNA methylation directs a time-
dependent repression of transcription initiation. Curr Biol 7: 157-165. 
 
Kouzarides, T. (2002) Histone methylation in transcriptional control. Curr Opin Genet 
Dev 12: 198-209. 
 
Leonhardt, H., Page, A.W., Weier, H.U., and Bestor, T.H. (1992) A targeting sequence 
directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. 
Cell 71: 865-873. 
 
 108
Levine, A., Yeivin, A., Ben-Asher, E., Aloni, Y., and Razin, A. (1993) Histone H1-
mediated inhibition of transcription initiation of methylated templates in vitro. J 
Biol Chem 268: 21754-21759. 
 
Murray, E.J., and Grosveld, F. (1987) Site specific demethylation in the promoter of 
human gamma-globin gene does not alleviate methylation mediated suppression. 
Embo J 6: 2329-2335. 
 
Okano, M., Xie, S., and Li, E. (1998) Cloning and characterization of a family of novel 
mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19: 219-220. 
 
Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999) DNA methyltransferases Dnmt3a 
and Dnmt3b are essential for de novo methylation and mammalian development. 
Cell 99: 247-257. 
 
Razin, A., and Shemer, R. (1995) DNA methylation in early development. Hum Mol 
Genet 4 Spec No: 1751-1755. 
 
Stancheva, I., and Meehan, R.R. (2000) Transient depletion of xDnmt1 leads to 
premature gene activation in Xenopus embryos. Genes Dev 14: 313-327. 
 
Turner, B.M. (2000) Histone acetylation and an epigenetic code. Bioessays 22: 836-845. 
 
Veenstra, G.J., and Wolffe, A.P. (2001) Constitutive genomic methylation during 
embryonic development of Xenopus. Biochim Biophys Acta 1521: 39-44. 
 
 
 
 
 
 
 
 
 
 
 
 109
FIGURES 
 
 
 
 
 
Figure A.1:  Methylation status determination by methyl sensitive restriction digest.  
Methyl pGL3-CMV is completely methylated.  Linear pGL3-CMV is sensitive to BstUI 
digestion, while linear methylated pGL3-CMV is not. 
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Figure A.2:  Transcriptional activity of transgenically integrated methylated pGL3-CMV 
versus unmethylated pGL3-CMV promoters in Xenopus laevis during early 
embryogenesis.  Completely methylated pGL3-CMV is transcriptionally active in 
transgenic Xenopus embryos during early development, but rapidly silenced compared to 
unmethylated pGL3-CMV.  Percent relative quantity of methylated pGL3-CMV 
luciferase transcripts are normalized to genomic transgene copies and compared to 
unmethylated pGL3-CMV luciferase transcripts at a relative level of 100%; error bars are 
+standard error of the mean.  Methylated pGL3-CMV qRT-PCR samples that did not 
reach threshold levels are indicated by (*). 
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APPENDIX B*  
 
TESTING THE EFFECTS OF FSHD CANDIDATE GENE EXPRESSION IN 
VERTEBRATE MUSCLE DEVELOPMENT 
 
 
*Data and writing is adapted from: 
  
S.W. Long, R.D. Wuebbles, M.L. Hanel, and P.L. Jones. Testing the effects of FSHD candidate gene expression on vertebrate 
muscle development (Int J Clin Exp Pathol, 2010;3(4):386-400) 
 
 
INTRODUCTION 
 
FSHD is now recognized as one of the most prevalent forms of muscular 
dystrophy in adults (http://www.orpha.net).  Prominent features of this myopathy are the 
progressive weakening of the skeletal muscles in the face, shoulder girdle, and the upper 
arms, and these muscular aspects are often combined (>50% of patients) with retinal 
vasculopathy (Fitzsimons et al., 1987; Padberg et al., 1995). The genetic lesion leading to 
the most prominent form of FSHD (FSHD1A), accounting for ~98% of FSHD patients, is 
an autosomal dominant contraction of the D4Z4 repeat array at chromosome 4q35 below 
11 copies (van Deutekom et al., 1993; Wijmenga et al., 1992).  This contraction leads to 
hypomethylation of the D4Z4 repeats, which has been proposed to lead downstream to 
the misregulation of one or more of the 4q35 localized genes including FRG1, ANT1, 
FRG2, DUX4, and DUX4c (van Overveld et al., 2003).  However, none of these 
candidate genes has consistently been shown to exhibit significantly altered RNA 
expression levels in affected FSHD muscle biopsies compared to unaffected controls 
(Dixit et al., 2007; Gabellini et al., 2002; Gabellini et al., 2006; Jiang et al., 2003; 
Klooster et al., 2009; Rijkers et al., 2004; Snider et al., 2009; Winokur et al., 2003b).  
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Multiple issues complicate these expression analyses including large differences within 
an affected muscle and potentially at the site of biopsy, the bias focusing on FSHD gene 
misexpression exclusively in the skeletal muscle lineage, and the potential that FSHD 
gene misexpression occurs during cell differentiation (Barro et al., 2008; Bodega et al., 
2009; Morosetti et al., 2007; Rijkers et al., 2004).  Thus, without knowing when and 
where in human muscle development gene misexpression leading to FSHD occurs, the 
cause of the FSHD pathophysiology has remained controversial. 
 To circumvent the ambiguity of RNA expression analyses, we have taken a 
developmental approach to the problem by first addressing the normal function of an 
FSHD candidate gene during development and then assaying the effect of overexpression 
of an FSHD candidate gene on vertebrate development.  The system for these studies is 
the early development of Xenopus laevis.  Our initial analysis focused on understanding 
the function and expression of one candidate gene, frg1 (Hanel et al., 2009; Wuebbles et 
al., 2009).  FRG1 is a highly conserved gene of unknown function that is overexpressed 
in FSHD patient derived myoblasts undergoing myogenic differentiation (Bodega et al., 
2009).  These studies found that frg1 is required for the normal development of the 
vertebrate musculature and vasculature (Hanel et al., 2009; Wuebbles et al., 2009).  
Consistent with a role in FSHD pathology, systemically elevated levels of frg1 led to 
phenotypes specifically in the vertebrate musculature and vasculature which strongly 
correlated to the two most common symptoms of FSHD, dystrophic muscle and increased 
angiogenesis (Hanel et al., 2009; Wuebbles et al., 2009).  Thus, developmentally, FRG1 
overexpression fits the criteria for being causal for FSHD pathology. 
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We have continued our analysis with three additional FSHD candidate genes, 
DUX4, DUX4c, and PITX1 (Ansseau et al., 2009; Dixit et al., 2007; Kowaljow et al., 
2007).  DUX4 and DUX4c are encoded within open reading frames (ORFs) of different 
4q35 D4Z4 repeat units within or near the FSHD deletion (Gabriels et al., 1999; Wright 
et al., 1993).  Although D4Z4 repeat arrays exist in multiple loci in the genome (Winokur 
et al., 1996), RNAs originating specifically from the 4q35 localized D4Z4/DUX4 and 
D4Z4/DUX4c loci are increased in certain FSHD patient-derived muscle cells (Ansseau 
et al., 2009; Dixit et al., 2007; Kowaljow et al., 2007).  A normal cellular or 
developmental role for the 4q35 DUX4 protein, if any, has not been described; however, 
expression of the currently accepted 4q35 derived DUX4 protein is highly toxic to all 
cells leading to a rapid onset of apoptosis (Bosnakovski et al., 2008b; Kowaljow et al., 
2007).  This apoptotic effect of DUX4 expression is postulated to be from direct 
competition with the regulatory targets of PAX3/PAX7 and is inhibited by elevated 
expression of PAX3 or PAX7 (Bosnakovski et al., 2008b).  Interestingly, in a cell culture 
system, DUX4 has been shown to bind the promoter and activate expression of PITX1, a 
non-4q35 localized FSHD candidate gene whose expression has been found to be 
upregulated in FSHD muscle, providing an alternative mechanism for DUX4-mediated 
pathology (Dixit et al., 2007).  DUX4c, located within a partial D4Z4 unit 42 kb proximal 
to the FSHD-associated D4Z4 array, is identical to DUX4 through their N-terminal 
double homeobox domains however they have differing C-terminal amino acid sequences 
(Wright et al., 1993).  DUX4c expression has been detected in muscle cells where it is 
proposed to act as a myogenic regulator and inhibitor of myoblast differentiation 
(Ansseau et al., 2009; Bosnakovski et al., 2008a).  
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In this study, we assayed the effects of expression of human DUX4 and DUX4c, 
as well as the X. laevis ortholog of PITX1 on early vertebrate development, with 
particular attention to muscle growth and differentiation.  We show that DUX4 
expression and pitx1 overexpression both lead to massive cellular loss that is not muscle 
specific.  With DUX4 in particular the cellular loss occurred at extremely low expression 
levels and was cell-type independent indicating that this protein is highly toxic to all 
vertebrate cells and this toxic effect was not specific to muscle.  DUX4c expression did 
not lead to any observable change in muscle development or differentiation or changes in 
the expression of the myogenic regulators myf5 or myoD in Xenopus.  Contradictory to 
what has been reported in cell culture, we found that both DUX4 and DUX4c 
significantly reduced expression levels of pitx1 transcripts in our animal model.  
Together with our previous studies on frg1, this presents the first analysis for direct 
comparison of the effects of expression of the main FSHD candidate genes in a 
developing vertebrate system. 
 
RESULTS  
 
Expression of DUX4 and pitx1 lead to cellular loss while DUX4c expression has 
minimal effect on development 
 
 The early development of X. laevis was used as a model system to determine the 
effects of FSHD candidate genes DUX4, DUX4c, and pitx1 expression levels on 
vertebrate development.  In normal human tissues, DUX4 and DUX4c expression is 
undetectable and the proteins are neither required for nor involved in any known normal 
cellular function.  The human 4q35 DUX4 and DUX4c genes are not conserved outside 
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of their double homeobox domains and Xenopus do not possess any orthologs.  
Therefore, we assayed the effects of the presence of DUX4 or DUX4c during muscle 
development compared to a background of no expression.  Conversely, the pitx1 
transcription factor, as was the case with frg1, is highly conserved between mammals and 
Xenopus in protein sequence, function, and developmental expression (Chang et al., 
2001).  For this gene, we assayed the effect of increasing its expression during 
development as well as expression outside its normal developmental profile. 
To determine the effects of DUX4 and DUX4c expression, and elevated levels of 
pitx1 during development, one side of early four cell-stage X. laevis embryos were 
injected with the corresponding mRNAs as well as mRNA encoding the EGFP marker 
mRNA.  The developing embryos resulted in animals overexpressing the desired proteins 
on the injected side (confirmed by fluorescence) while co-developing a control, 
uninjected side.  To study any tissue-specific effects on muscle, titration experiments 
with DUX4, pitx1, and DUX4c mRNA were performed and the numbers of abnormally 
developing embryos were observed.  Abnormal development was scored as any 
abnormality observed during development, regardless of severity.  Similar to previous 
data from cultured myoblasts, we found that our initial injection level of 100 pg DUX4 
mRNA was highly toxic to the embryos (Figure B.1A & B.1K). Embryos were arrested 
by stage 9 with an overall apoptotic appearance throughout the entire embryo. This 
severe phenotype occurred in all embryos injected with 100 ng (n = 13), 50pg (n = 26), 
and 25 pg (n = 19) examined, although developmental arrest occurred slightly later with 
less DUX4 mRNA (Figure B.1A & B.1K).  This severe apoptotic phenotype resulting in 
early developmental arrest was never observed in EGFP injected (n = 119) or uninjected 
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(n = 600) controls (Figure B.1J & B.1K).  Unlike 100 pg, injection of 10 pg DUX4 
mRNA (n = 426) resulted in toxicity generally restricted to the injected side 72 hours 
post-injection (Figure B.1B). The heavy cellular loss in the injected side led to a small 
embryo and eventual arrest, likely due to gastrulation or neurulation defects caused by 
DUX4 expression.  Further reducing the level to 1 pg DUX4 mRNA (n = 166) resulted in 
a low percentage of animals which were able to progress through and complete closure of 
their neural tubes (Figure B.1C); however, all 1 pg DUX4 injected embryos tested 
showed massive apoptosis by TUNEL staining (Figure B.1D).  A further 2-fold reduction 
to 0.5 pg DUX4 mRNA (n = 213) resulted in a significant increase of normal developing 
embryos, suggesting the effect of DUX4 is either cellular toxicity or nothing (Figure 
B.1E). Even in these embryos, the fluorescence of the EGFP appeared patchy (Figure 
B.1F), suggesting that though they appeared to have progressed through development 
normally, DUX4 had still led to cellular loss.  Therefore, consistent with other systems, 
DUX4 expression is extremely cytotoxic in developing Xenopus (Bosnakovski et al., 
2008b; Kowaljow et al., 2007).  
DUX4 is capable of inducing PITX1 expression in mouse C2C12 cell culture 
suggesting PITX1 misexpression as a possible mechanism for DUX4-mediated pathology 
(Dixit et al., 2007).  To determine the effect of aberrantly induced pitx1 expression, we 
bypassed DUX4 expression and microinjected mRNA encoding Xenopus pitx1 into 
embryos as above.  Similar to injections of DUX4 mRNA, we found that both 500 pg 
(n=272) and 300pg (n=122) of pitx1 mRNA led to early embryo arrest while injection of 
150 pg pitx1 (n=254) led cellular loss specifically on the injected side leading to a curled 
phenotype and gastrulation or neurulation defects (Figure B.1G & B.1K).  Injections of 
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50 pg pitx1 mRNA (n=122) had no obvious effects on development (Figure B.1H & 
B.1K).  Thus, while pitx1 overexpression is cytotoxic, developing embryos are much 
more tolerant of pitx1 overexpression than DUX4 expression suggesting that DUX4 
cytotoxicity is not mediated through the activation of pitx1. 
The analysis of the third FSHD candidate gene, DUX4c, produced results that 
were a stark contrast to the effects of DUX4 and pitx1.  Microinjections of as much as 
1ng of DUX4c mRNA (n=477) only lead to a modest increase over uninjected 
background levels of developmental abnormalities, yet still far fewer and less in severity 
than seen with a 2000-fold lower amount of DUX4 mRNA (Figure B.1I & B.1K).  
Because DUX4c shares an identical double homeobox domain with DUX4, the fact that a 
2000-fold increase in mRNA produced only minor developmental problems indicates that 
a strictly competitive interaction with Pax3 and Pax7 for DNA regulatory targets is not 
responsible for the DUX4 phenotype.  
 
Cytotoxicity mediated by DUX4 and pitx1 is not muscle specific 
 The symptoms associated with FSHD are primarily muscular and often combined 
with a less prominent vascular component.  Taking into account the generally accepted 
model whereby the FSHD1A deletion leads to an epigenetic upregulation of gene 
expression, one would expect the effect of a viable candidate gene’s systemic expression 
to be primarily seen in tissues affected in FSHD as is the case with frg1.  In order to 
determine if muscle was specifically affected by DUX4, pitx1, or DUX4c expression, 
injected embryos were analyzed for differentiated muscle and neurologic tissue by 
immunostaining with the 12/101 or NCAM antibodies, respectively (Figure B.2 & B.3).  
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Due to the severe loss of tissue in the 1 pg DUX4 and 150 pg pitx1 injected animals, the 
figures depict some of the best developing and staining animals, as most failed to form a 
complete neural tube closure and were consequently too curled to capture the staining 
pattern in photographs.     
Immunostained animals were qualitatively determined to exhibit normal, 
depleted, or absent levels of immunostaining on the mRNA injected side (Figure B.2).  
Embryos scored as depleted included those exhibiting highly dispersed but significant 
staining, missing somites and somite disruptions, and a significantly thinner somite area.   
DUX4 injected embryos were first analyzed for affects on the developing muscle.  
Qualitative inspection of 1 pg DUX4 injected embryos stained with 12/101 (n = 45, 
missing n = 22, depleted n = 23) indicate a severe loss of muscle tissue by the lack of 
12/101 immunostaining specifically on the injected side of the embryo (Figure B.2A’ and 
B.2B’ compared to Figure B.2A and B.2B).  However, transverse paraffin sectioning 
revealed these animals had a weak appearance of staining due to a build up of cellular 
debris between the 12/101 stained muscle near the notochord/neural tube and the lateral 
edge of the injected side (Figure B.2B and B.2F).  The area of the myotome on the 
injected side was significantly decreased due to cellular loss.  We find a large increase in 
the number of embryos with normal 12/101 staining when we inject 0.5 pg DUX4 mRNA 
(n = 87, missing n = 27, depleted n = 31) and this increase in normally stained embryos 
corresponded well to the number of normally developing embryos (Figure B.2I’ 
compared to B.2I, B.2J, Figure B.3). 
Muscle is the primary affected tissue in FSHD.  To determine if DUX4 was 
similarly cytotoxic to tissues unaffected in FSHD, neurons were assayed in 1 pg DUX4 
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injected embryos (n = 24).  Immunostaining for NCAM, which at stage 34 of Xenopus 
development is confined to neural tissue, resulted in levels of missing (n = 13) and 
depleted (n = 11) NCAM staining similar to that of 12/101 (Figure B.3).  In several 
animals the NCAM staining was specifically depleted in the area of the eye (Figure B.2D 
& B.2H) and transverse sections revealed that often the neural tube staining was depleted 
as well (Figure B.2C & B.2H).  We conclude that the cellular loss mediated by DUX4 is 
not restricted to muscle. 
Embryos injected with pitx1 mRNA were similarly analyzed for muscle and 
neuronal defects.  The injection of pitx1 led to developmental abnormalities similar to 
those seen with DUX4 albeit at a much higher concentration of mRNA.  As with the 
DUX4 injections, 150 pg pitx1 mRNA injections (n = 64) led to depletion (n = 32) and 
loss (n = 31) of 12/101 immunostaining from the injected side (Figure B.2Q’ compared to 
B.2Q, B.2R).  This effect was dose dependent, with 50 pg pitx1 mRNA (n = 71) causing 
almost no loss of 12/101 immunostaining (missing n = 2, depleted n = 11) (Figure B.2U’ 
compared to B.2U, B.2V).  Similarly, the 150 pg pitx1 injection (n = 8) led to depleted (n 
= 6) or missing (n = 2) NCAM immunostaining (Figure B.2S & B.2T), while 50 pg pitx1 
injection (n = 19) did not (Figure B.2W & B.2X). 
 Despite the lack of any significant gross developmental defects (Figure B.1I), 
DUX4c injected embryos were assayed for muscular and neuronal alterations.  
Differences were expected in the myotome based on previous findings of DUX4c 
mediated inhibition of myoblast differentiation (Ansseau et al., 2009; Bosnakovski et al., 
2008a).  However, when stained with 12/101, 1 ng DUX4c mRNA injected embryos (n = 
89) still displayed normal immunostaining (Figure B.2M’ compared to B.2M, B.2N) with 
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abnormalities (missing n = 0, depleted n = 10) comparable to EGFP mRNA injected 
controls (n = 41, missing n = 0, depleted n = 3) (Figure B.2Y, B.2Y’, Figure B.3).  
Similarly, the NCAM staining of DUX4c injected embryos (Figure B.2O & B.2P) had 
abnormalities (n = 14, missing n = 0, depleted n = 1) similar to NCAM stained EGFP 
mRNA injected controls (n = 15, missing n = 0, depleted n = 1) (Figure B.3).  We 
conclude that DUX4c levels have no effect on the developing musculature or neurons. 
 
DUX4 eliminates myoD, myf5, and pax3 expression profiles 
 DUX4 expression led to the loss of 12/101 immunostaining indicating 
differentiated muscle was degraded or missing.  To determine if DUX4 expression leads 
to a loss of muscle cell precursors, in situ hybridizations with probes against myoD, myf5, 
or pax3 were performed (Figure B.4).  In stage 34 embryos from the 1 pg DUX4 mRNA 
injections, the expression of all three of these markers was missing in a large majority 
(myoD n = 60/62; myf5 n = 12/20; pax3 n = 23/28) (Figure B.4A’, B.4B’, & B.4C’ 
compared to B.4A, B.4B, & B.4C).  Assaying earlier in development, stage 20 DUX4 
injected embryos were missing expression of pax3 (n = 11/20) (Figure B.4G).  Although 
the markers myf5 and pax3 were depleted, the entire tissue, including neural tissue was 
affected.  When taken into consideration with our previous findings that the DUX4-
meidated defects began at gastrulation (Figure B.1A) and we conclude that the DUX4-
mediated cellular loss occurs prior to stage 20 and therefore is clearly not muscle 
specific.   
Unlike DUX4, DUX4c had little to no observable effect on the expression of 
myoD, myf5, and pax3 (myoD n = 5/31; myf5 n = 0/8; pax3 n = 0/30) (Figure B.4D’, 
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B.4E’, & B.4F’ compared to B.4D, B.4E, & B.4F, respectively).  Similarly, no change 
was observed in pax3 staining at stage 20 in embryos injected with 1 ng DUX4c mRNA 
(n = 0/12) (Figure B.4H).  Quantitative reverse transcription PCR (qRT-PCR) was used 
to confirm there is no change in transcript levels of the myogenic regulators myoD or 
myf5 when injected with 1 ng DUX4c mRNA.  Neither stage 20 embryos (n = 30) nor 
stage 34 embryos (n = 20) have statistically significant differences in myoD or myf5 
transcript levels when compared to EGFP mRNA injected controls normalized to gapdh 
(Figure B.5).  Thus, DUX4c has no effect on muscle precursors or myogenic regulators.  
Moreover, we found no significant changes of myogenic regulators by qRT-PCR on 
intact tissue from 1 pg DUX4 stage 34 injected embryos, further suggesting DUX4 has a 
strictly apoptotic role (Figure B.5).   
 
DUX4 and DUX4c expression reduce endogenous pitx1 expression 
 FSHD affected muscle has elevated levels of PITX1 transcript and in cell culture 
assays DUX4 activates transcription of PITX1 (Dixit et al., 2007).  Endogenous pitx1 
expression was examined by in situ hybridization in 1 pg DUX4 and 1 ng DUX4c injected 
stage 34 X. laevis embryos.  During early X. laevis development (prior to hind-limb 
development), observable pitx1 expression is confined to the cement and pituitary glands, 
and this expression pattern is not altered by expression of either DUX4 (Figure B.6A’ 
and B.6A; n = 23) or DUX4c (Figure B.6B’and B.6B; n = 27).  Although there is no 
statistically significant change in stage 20 embryos, surprisingly, analysis of stage 34 
transcript levels by qRT-PCR showed that pitx1 expression was actually reduced by 
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DUX4c and DUX4 when compared to EGFP controls (p-value < 0.05) (Figure B.6D).  
We conclude that neither DUX4 nor DUX4c expression activates pitx1 expression in vivo. 
 
DISCUSSION 
 
Multiple candidate genes have been proposed as causal of FSHD pathophysiology 
based on selective upregulation in FSHD patient-derived tissues or cell lines (Dixit et al., 
2007; Gabellini et al., 2002; Klooster et al., 2009; Reed et al., 2007; Rijkers et al., 2004).  
However inconsistent results, likely due in part to variations within and between FSHD 
patient biopsies as well as culturing conditions, have made it unclear which gene(s) are 
misexpressed.  Previously we used X. laevis as a developing vertebrate model to analyze 
the effects of altering the expression levels of frg1.  In the current study, we have used 
this same system to similarly analyze the effects of three additional FSHD candidate 
genes, DUX4, DUX4c and pitx1, on vertebrate muscle development. 
X. laevis is a well-defined model system for muscle development with many 
advantages including external development, cells grow and differentiate under normal 
growth and environmental conditions giving rise to all tissues, and gene expression is 
easily manipulated through microinjection or transgenesis.  In addition, Xenopus and 
humans share high levels of conservation of tissue organization, developmental 
processes, genes, and proteins.  For example, the conservation of some muscle and FSHD 
associated proteins between human and Xenopus are as follows:  FRG1 (80% identity, 
88% similar), PITX1 (77% identity, 84% similar), PAX3 (91% identity, 96% similar) 
including 100% conservation of the homeodomain (aa 220-277), PAX7 (88% identity, 
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94% similar) including 100% conservation of the homeodomain (aa 217-274), MYOD1 
(65% identity, 75% similar), and MYF5 (69% identity, 84% similar), as determined by 
alignments using NCBI BLAST Alignp.  In contrast, DUX4 and DUX4c belong to the 
DUX family of double homeobox domain proteins but do not have Xenopus orthologs.  
In fact, when considering the entire protein sequence, including that residing outside their 
homeodomains, they both completely lack evolutionary conservation and appear to be 
unique to humans.  Even the most closely related DUX4 ORFs in mice (Bosnakovski et 
al., 2009; Clapp et al., 2007; Kawazu et al., 2007; Wu et al.) show levels of sequence 
similarity (31% amino acid identity for the Duxbl protein aligned to DUX4 using the 
ClustalW function of BioEdit Sequence Alignment Editor software) far below what is 
expected for mouse to human conservation.  Without any clear ortholog available, the 
human sequences for DUX4 and DUX4c were used for these studies. 
We have confirmed the toxic effect of DUX4 expression in the context of normal 
vertebrate development during stages of active myogensis.  By differential staining of 
neuronal and muscle tissues in DUX4 injected Xenopus embryos, we observe massive 
cellular loss of both tissue types and thus toxicity to not be muscle specific.  Moreover, 
DUX4 injected X. laevis embryos show heavy TUNEL staining, indicating the function 
of DUX4 to induce apoptosis is conserved in Xenopus.  Interestingly we have identified 
an extremely low threshold level of DUX4 mRNA (0.5 pg) required for developmental 
abnormalities in Xenopus, at which point embryos appear to be either apoptotic or normal 
on the injected side.  Although “non-toxic levels” of DUX4 in myoblast cell culture has 
been shown to impair differentiation (Bosnakovski et al., 2008b), we observed no change 
in myotome development unless it was accompanied with generalized tissue apoptosis.  
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This observation suggests that DUX4 has an “all or nothing” effect in Xenopus; we 
observe either severe developmental consequences or no effect on normal development 
of the organism. 
The toxic effects of DUX4 are proposed to be due to the similarity of the 
homeodomains with those of myogenic regulators involved in development and 
regeneration such that DUX4 competes for their binding to regulatory sites (Bosnakovski 
et al., 2008b).  The DUX4 homeodomain sequences are similar to ortodenticle (otx) and 
paired (prd) classes of proteins (Bopp et al., 1986; Finkelstein et al., 1990; Hewitt et al., 
1994).  Otx and Pax proteins represent two families containing otx and prd 
homeodomains, respectively.  Otx1 and Otx2 function in the nervous system (Simeone et 
al., 2002), while the Pax3 and Pax7 proteins have known functions in the development of 
skeletal muscle and Pax7 in the maintenance of muscle satellite cells (Buckingham, 
2006).  In support of the DUX4 competition model, MyoD, a well characterized target of 
Pax3 activation during development and Pax7 in adult myogenesis (Olguin and Olwin, 
2004; Relaix et al., 2006; Tajbakhsh et al., 1997), was shown to be rapidly down 
regulated by DUX4 in a inducible C2C12 myoblast cell line system (Bosnakovski et al., 
2008b).  Considering Xenopus pax3 and pax7 homeodomains are 100% conserved with 
human PAX3 and PAX7, if DUX4 is functioning as a competitor of both PAX3 and 
PAX7 target genes, and consequently an antipodal regulator of myogenic genes in 
myoblasts, we would expect this competition to also be conserved in our study.  In 
phenotypic DUX4 injected embryos, we observed a reduced level of myoD and myf5 
staining by in-situ hybridization when compared to EGFP controls.  Furthermore, DUX4 
injected embryos showed that pax3 transcripts, the upstream regulator of myoD, was 
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absent by stage 20 of Xenopus development indicating DUX4 toxicity precedes muscle 
development.   These data lead us to conclude that the DUX4 injected Xenopus 
phenotype is likely due to massive apoptosis on the injected side of the individuals and 
not resulting from muscle cell specific competition for pax3/7 targets.  Taking into 
account that an aberrant increase in apoptosis is not generally considered to be part of the 
muscle pathology in FSHD (Sandri et al., 2001; Winokur et al., 2003a), this data could be 
consistent with DUX4 having a role in FSHD muscle pathology provided DUX4 is either 
only expressed at very low levels if at all under normal conditions and is only 
overexpressed in the muscle cell precursors of FSHD patients and not any other cells. 
DUX4c, located within a truncated and inverted D4Z4 repeat located just 
centromeric from the FSH1A locus, has been shown to be up-regulated in FSHD 
(Ansseau et al., 2009; Wright et al., 1993).  The gene encodes an ORF identical to DUX4 
except for differing in the last 82 amino acids which are substituted with 32 unrelated 
amino acids.  Interestingly, the C-terminal substitution leaves DUX4c with the exact 
homeodomains found in DUX4.  This, in theory, would enable DUX4c to interact with 
all of the same genetic targets of DUX4.  Therefore, considering 100% conservation of 
pax3/7 homeodomains from human to Xenopus, expression of DUX4c should also 
compete with the pax3 and pax7 for myogenic target genes and thus lead to myogenic 
abnormalities in Xenopus.  Interestingly, 1ng DUX4c mRNA injections (2000 fold over 
DUX4 threshold levels) produce only a slight increase in abnormal Xenopus development, 
further indicating the DUX homeodomains do not compete with pax3 or pax7 for 
myogenic target genes.  In two previous studies, DUX4c has been shown to inhibit 
myoblast differentiation and down-regulate MyoD (Ansseau et al., 2009; Bosnakovski et 
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al., 2008a).  Oddly, both studies investigate effects of DUX4c on Myf5 expression in 
identical myoblast cell lines and find opposite results; one finding Myf5 is down-
regulated (Bosnakovski et al., 2008a), while the other shows an up regulation of Myf5 
(Ansseau et al., 2009). Interestingly, differences between FSHD and control DUX4c 
levels were only observed in myotubes, after the effects on myoblast differentiation 
would have passed (Ansseau et al., 2009). We observed no obvious changes in staining 
patterns for myoD or myf5 in DUX4c injected Xenopus embryos by in-situ hybridization 
and mRNA levels are not significantly different from that of EGFP injected controls by 
qRT-PCR.  This study on the effects of DUX4c on myogenic regulators in a vertebrate 
going through muscle development leads us to conclude that DUX4c expression has no 
overt effects on muscle development and is not consistent with DUX4c expression having 
a role in FSHD pathology. 
The FSHD candidate PITX1 is a member of the paired family of homeodomain 
transcription factors (Tremblay et al., 2000).  Multiple studies focused on PITX1 shows it 
is involved in specification of hind limb identity, as well as left-right symmetry (Cole et 
al., 2003; Lanctot et al., 1999; Logan and Tabin, 1999; Shapiro et al., 2004; Szeto et al., 
1999; Tanaka et al., 2005).  It was recently shown that DUX4 could activate transient 
expression of a reporter gene fused to the PITX1 promoter as well as the endogenous 
PITX1 gene in transfected C2C12 cells (Dixit et al., 2007).  Although the sequence of the 
pitx1 promoter is unknown in X. laevis, the fact that DUX4 maintains its characteristic 
ability to induce apoptosis suggests it is interacting with its conserved targets.  Taking 
into consideration that DUX4 and DUX4c contain identical homeodomains we tested 
their potential to regulate pitx1.  At stage 34 pitx1 is characteristically expressed at high 
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levels in the cement gland (Chang et al., 2001; Hollemann and Pieler, 1999; Schweickert 
et al., 2001).  We found no obvious increase of pitx1 in DUX4 or DUX4c injected 
embryos.  Interestingly, we did see a statistically significant (p-value <0.05) decrease in 
pitx1 mRNA when DUX4c or DUX4 injected stage 34 tadpoles were subjected to qRT-
PCR.  We conclude that neither DUX4 nor DUX4c induce pitx1 in Xenopus and DUX4-
mediated apoptosis is not mediated through activation of pitx1.  To directly test the 
effects of overexpression of pitx1, we circumvented the issues related to DUX4 
expression by directly increasing pitx1 through microinjection and determine the effects 
on Xenopus development.  As with DUX4, we observed severe, general (not muscle cell 
specific) developmental abnormalities when pitx1 was overexpressed in Xenopus, 
agreeing with previous reports (Schweickert et al., 2001). Like DUX4, these abnormalities 
likely arise from the induction of apoptosis, as increased pitx1 expression has been shown 
to directly lead to increased p53 expression and cellular loss (Liu and Lobie, 2007).  This 
result is consistent with PITX1 playing a role in FSHD assuming it is only overexpressed 
in muscle lineages of FSHD patients. 
 At this point, the mechanism of FSHD pathophysiology remains unknown.  In 
total we tested the effects of systemic overexpression of four FSHD candidate genes on 
vertebrate development in our Xenopus system.  We have found systemic overexpression 
of DUX4c has little effect while DUX4 and pitx1 produce a general cytotoxicity to all 
cell types in developing embryos.  FSHD is likely an epigenetic disorder but it is not 
known if the cause of FSHD is a misregulation of a gene specifically restricted to skeletal 
muscle and its precursors or if there is a global misregulation of a gene with skeletal 
muscle myogenesis being specifically susceptible.  Only if it is the former, and DUX4 
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and PITX1 were exclusively overexpressed in skeletal muscle precursors, could they 
have a role in FSHD pathology.  We know no mechanism whereby DUX4 or PITX1 
cytotoxicity could produce the vasculature phenotype strongly associated with FSHD.  In 
respect to DUX4c we conclude it likely has no role in FSHD pathology, however, it is 
possible multiple candidates including DUX4c could function together to produce a 
synergistic effect ultimately resulting in FSHD-like pathology.  This compares poorly to 
FRG1 from our previous studies where systemic overexpression of frg1 could 
recapitulate both major symptoms of FSHD in Xenopus, dystrophic muscle and increased 
angiogenesis (Hanel et al., 2009; Wuebbles et al., 2009).  Taken together, the functional 
and phenotypic data point to FRG1 as the most likely candidate whose misexpression, 
either systemically or specifically during myogenesis, leads to FSHD pathology. 
 
MATERIALS AND METHODS 
 
Frog husbandry 
Adult X. laevis were purchased from Xenopus Express. All procedures were 
carried out in accordance with established UIUC IACUC approved protocols for animal 
welfare. 
 
Plasmid constructs and RNA production 
The vectors pCIneo DUX4 and pCIneo DUX4c were generously provided by Dr. 
Alexandra Belayew (Ansseau et al., 2009; Gabriels et al., 1999).  The plasmids for 
EGFP, myoD, pax3, and myf5 RNA have been previously described (Hanel et al., 2009). 
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The pitx1 cDNA was produced by RT-PCR using primers 5’ gtgattgaccatggattcctttaaagg 
3’ and 5’ tcaactgttatattggcaagcattgag 3’, cloned into pGEM T-Easy (Promega) and 
sequenced.  The cDNA was subcloned into the EcoRI and XbaI sites of pcDNA3.1 
(Invitrogen).  Production of EGFP mRNA was performed as previously described (Hanel 
et al., 2009). For DUX4, DUX4c and pitx1 mRNA, constructs were linearized and 
capped mRNA was generated using T7 RNA polymerase and the mMessage mMachine 
kit (Ambion, Inc). 
 
Xenopus embryo injections 
In vitro fertilized embryos were generated as described (Hanel et al., 2009).  
Embryos were microinjected after completion of the two cell stage, as indicated by the 
beginning of the second cleavage, in 1X MMR with 3% Ficoll and incubated at 19°C.  
Between 3-6 hours after injection, embryos were transferred to 0.1X MMR with 3% 
Ficoll.  After 24-36 hours embryos were either peeled and fixed for stage 18-22 embryos 
or cultured in 0.1X MMR until the desired stage. After neural tube closure all injected 
embryos were sorted based on left, right or bilateral fluorescence. DUX4 mRNA was 
injected at 500pg, 250pg, 100pg, 10pg, 1pg, and 0.5pg along with 500pg EGFP mRNA.  
DUX4c mRNA was injected at 1 ng along with 500pg EGFP. pitx1 was injected at 150pg 
and 50pg along with 500pg EGFP. Control EGFP mRNA injections were performed at 
500pg.  
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TUNEL assay 
TUNEL staining of whole-mount Xenopus embryos was carried out using a 
protocol adapted from Hensey and Gautier (Hensey and Gautier, 1997).  All procedures 
were carried out at room temperature unless noted otherwise.  Embryos were fixed for 1 
hr. in MEMFA, (100 mM MOPS (pH 7.4), 2 mM EGTA, 1 mM MgSO4, 4% 
formaldehyde). Embryos were washed in methanol 2 x 30 min. and stored in methanol at 
-20°C.  For rehydration, half of methanol was replaced with PBS and washed 5 x 5min.  
The embryos were washed with PBT (0.2% Tween-20 in PBS), 2 x 15 min., followed by 
2 x 15 min. washes in PBS.  Embryo pigment was removed by treatment for 1-2 hours in 
1% H2O2, 5% Formamide, and 0.5X SSC under bright light, and washed 3 x 15 min. in 
PBS.  Embryos were transferred to terminal deoxynucleotidyl transferase, (TdT), buffer 
(Invitrogen) and washed for 30 min.  End labeling was carried out overnight in TdT 
buffer containing 0.5 mM digoxygenin-dUTP (Roche Diagnostics), and 150 U/ml TdT 
(Invitrogen). Embryos were then washed 2 x 1 hr. in PBS/1 mM EDTA, at 65°C, 
followed by 4 x 1 hr. in PBS. Detection and chromogenic reaction was carried out as 
previously described (Harland, 1991). Embryos were viewed and stored following 
rehydration in 1X PBS.   
 
In situ hybridizations 
Embryos were staged according to Nieuwkoop and Faber (Nieuwkoop and Faber, 
1994), fixed 1-2 hrs in MEMFA, washed 2 x 30 min in 100% methanol and stored in 
100% methanol at -20°C until use. The EGFP, Xenopus myoD, pax3, and myf5 antisense 
probes generated as previously described (Hanel et al., 2009). The pitx1 probe was 
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generated by linearizing pGEM pitx1 with SalI and using T7 RNA polymerase 
transcription to generate digoxigenin (DIG) -11-UTP (Roche Diagnostics) antisense RNA 
probes.  In situ hybridizations were performed according to standard methods (Harland, 
1991) and detected with alkaline phosphatase (AP) linked anti-DIG antibody (Roche 
Diagnostics) and the chromogenic substrates BCIP (5-Bromo-4-chloro-3-indolyl 
phosphate, toluidine salt) and NBT (Nitro blue tetrazolium chloride) (Roche 
Diagnostics).  Embryos were refixed overnight in Bouin’s fixative, followed by washing 
in 70% ethanol/30% PBS-Tween 0.1%, and pigment was removed by treatment for 1-2 
hours in 1% H2O2, 5% Formamide, and 0.5X SSC under bright light. Embyos were then 
washed in methanol 10 minutes and transferred to 1mM EDTA in PBS or glycerol for 
analysis and photography.  
 
Immunohistochemistry 
Embryos were staged and fixed as above, rehydrated in PBS-DT (1%DMSO, 1% 
Tween-20) and washed for 15 min in PBS-DT. Samples were blocked in 0.1M glycine, 
2% milk, 1% BSA, 1% Tween-20 and 1% DMSO for 4 hours at room temperature or 
overnight at 4°C.  Primary antibodies were diluted in blocking solution as follows: 
Skeletal muscle marker (12/101) diluted 1:3 or NCAM (4d) diluted 1:20 were incubated 
with embryos overnight at 4°C and detected using a HRP secondary (GE Healthcare) 
with a DAB staining kit from (Roche Diagnostics).  For paraffin sectioning, tadpoles 
immunostained for 12/101 or NCAM were dehydrated through an EtOH series, placed in 
50/50 EtOH/Xylene for 10 minutes, washed twice with 100% Xylene, emebedded in 
paraffin, positioned, and sectioned using a microtome.The 12/101 monoclonal antibody, 
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developed by J.P. Brockes, and the NCAM 4d monoclonal antibody, developed by U. 
Rutishauser, were obtained from the Developmental Studies Hybridoma Bank developed 
under the auspices of the NICHD and maintained at The University of Iowa, Department 
of Biological Sciences, Iowa City, IA 52242. 
  
qRT-PCR 
For each sample, total RNA was purified from 10 pooled embryos using Trizol 
reagent (Invitrogen) per manufacture’s protocol.  RNA was then treated with 1U RQ1 
DNase (Promega) per 1ug RNA for 30 min. at 37°C.  cDNA synthesis was preformed 
using 1ug of total RNA, 50ng of random hexamer, and Superscript III (Invitrogen) per 
manufacture’s suggested method.  Relative transcript levels were determined using 1ul of 
(1:20 diluted) cDNA (in triplicate), iQ SYBR Supermix, and gene specific primers 
(myoD:  5’ TGCCAAGAGTCCAGATTTCC 3’, 5’ 
CAGGTCTTCAAAGAAACTCATGTC 3’; myf5:  5’ 
GCTTATCTAGTATTGTGGATCGG 3’, 5’ CTGGTTTGTTGGGTGTAAGG 3’; pitx1:  
5’ CATGAGCAGAAGTGATTGAC 3’, 5’ GTAAAGTGAGTCCTTTGTCTCC 3’; 
gapdh:  5’ GGTGAAGGTTGGAATTAACGG 3’, 5’ GATCAGCTTGCCATTCTCAG 
3’) on a Bio-Rad iCycler IQ machine.  Experiments were preformed at least 3 times.  
Data analyses were preformed using the comparative Ct method and error bars are + 
standard error of the mean.  Changes were determined using the two tailed student’s t-test 
and considered significantly different at a P-value <0.05.        
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FIGURES 
 
 
 
 
 
Figure B.1:  DUX4 and pitx1 induce developmental abnormalities.  A) Injection of 100 
pg DUX4 mRNA leads to early developmental arrest (stage 9) and apoptosis compared to 
control embryos (arrow).  B and C) Injection of10 pg and 1 pg of DUX4 mRNA lead to 
developmental abnormalities on only the injected side of embryos (arrow head).   
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(Figure B.1 continued) D)  TUNEL assay on 1 pg DUX4 mRNA injection shows 
apoptosis in embryos (blue staining) compared to control injections (arrow).  E) Injection 
of 0.5 pg DUX4 mRNA allows some normal development (white arrow) compared with 
abnormal developing animals (blue arrow).  F) Normally developing 0.5 pg DUX4 
mRNA injected embryo is indicated by expression of co-injected EGFP (top) compared 
with the uninjected, non-fluorescing side (bottom, shown as a bright field image).  G) 
Injection of 150 pg pitx1 mRNA results in developmental abnormalities on the injected 
side (arrow head).  H) Embryos injected with 50 pg pitx1 mRNA are developmentally 
normal (compared with G).  I and J) The effect of 1ng DUX4c mRNA injection (I) is 
similar to EGFP controls (J).  K) Summary of percent abnormal embryos observed in 
mRNA injection experiments with number of animals analyzed for each set. 
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Figure B.2:  Expression of DUX4 and pitx1 but not DUX4c affect muscle and neural 
tissue development.  A-H) DUX4 (1 pg) injected embryos show depletion of 12/101 (A, 
B, E, and F) and NCAM (C, D, G, and H) immunostaining and cellular loss specifically 
on the mRNA injected side (*) in wholemount (A, A’, D, E, E’, and H) and transverse 
sections (B, C, F, and G).  Wholemount (I, L) and transverse sectioned (J, K) DUX4 (0.5 
pg) injected embryos have normal 12/101 (I, J) and NCAM (K, L) staining and myotome 
development on the injected side (*).  Wholemount (M, P) and transverse sectioned (N, 
O) DUX4c (1 ng) injected embryos have normal 12/101 (M, N) and NCAM (O, P) 
staining and myotome development on the injected side (*).  Wholemount (Q, T) and 
transverse sectioned (R, S) pitx1 (150 pg ) injected embryos show depletion of 12/101 (Q, 
R) and NCAM (S, T) immunostaining, abnormal myotome development and cellular loss 
specifically on the injected side (*).  Wholemount (U, X) and transverse sectioned (V, W) 
U-X) pitx1 (50 pg) injected embryos show no depletion of 12/101 (U, V) and NCAM (W, 
X) immunostaining and exhibit normal myotome development with no cellular loss on 
the injected side (*).  Wholemount (Y) 1 ng EGFP (1 ng) injected embryos have normal 
12/101 staining when compared to the uninjected side.  
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Figure B.3:  Summary of DUX4, DUX4c, and pitx1 mediated affects.  Graphic summary 
of results from Figure 2, showing percent of animals with missing, depleted, or normal 
12/101 and NCAM immunostaining. 
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Figure B.4: Effects of DUX4 and DUX4c on myoD, myf5, and pax3 mRNA expression 
patterns.  A-F) Stage 32-34 embryos were assessed for observable defects produced by 
DUX4 (A-C) and DUX4c (D-F) by in-situ hybridization for myogenic regulators.  
Injection of DUX4 (1 pg) mRNA into developing embryos decreased myoD (A, A’), 
myf5 (B, B”), and pax3 (C, C’) staining specifically on the injected side due to cellular 
loss.  Injection of DUX4c (1 ng) mRNA into embryos produces no observable changes in 
myoD (D, D’), myf5 (E, E’), or pax3 (F, F’) staining intensities when compared to the 
uninjected side.  G) Stage 20 embryos injected with DUX4 (1 pg) mRNA show depletion 
of pax3 staining before skeletal muscle development.  H) Stage 20 embryos injected with 
DUX4c (1 ng) mRNA does not affect pax3 staining.  I) Summary graph showing the 
percentage of observed in situ probe depleted embryos injected with DUX4 and DUX4c.
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Figure B.5:  Systemic DUX4c or DUX4 does not alter global levels of myoD or myf5.  
Levels of mRNA were quantified by qRT-PCR for myoD and myf5 in DUX4c (1 ng) or 
DUX4 (1 pg) injected embryos.  Fold change is normalized to gapdh levels and 
compared to EGFP mRNA at a relative level of 1; error bars are ± standard error of the 
mean.  
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Figure B.6:  Neither DUX4 nor DUX4c can induce pitx1 expression.  A-B) In situ 
hybridizations for pitx1 indicate that neither embryos injected with DUX4 nor DUX4c 
mRNA upregulate pitx1.  C) Graphic summary showing none of the embryos tested by in 
situ hybridization had obvious upregulation of pitx1, as illustrated by percent embryos 
without increased probe, with numbers of animals assayed. D) Quantification of pitx1 
mRNA in DUX4c (1 ng) or DUX4 injected embryos as determined by qRT-PCR. Fold 
change is normalized to gapdh and compared to EGFP at a relative level of 1; error bars 
are +standard error of the mean.  Significance (p-value < 0.05) is indicated by (*). 
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APPENDIX C* 
 
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) REGION GENE 1 
(FRG1) IS A DYNAMIC NUCLEAR AND SARCOMERIC PROTEIN 
 
*Data and writing is adapted from: 
 
Meredith L. Hanel, Chia-Yun Jessica Sun, Steven W. Long, Takako I. Jones, Derek Milner, and Peter L. Jones. 
Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric protein 
(Differentiation, 2010, submitted) 
 
Chia-Yun Jessica Sun, Silvana van Koningsbruggen, Steven W. Long, Michel Bellini, Lyne Levesque, William M. Brieher, 
Silvère M. van der Maarel, and Peter L. Jones FSHD region gene 1 (FRG1) is a dynamic RNA-associated, actin bundling protein 
(Manuscript in preparation) 
 
 
 
INTRODUCTION 
 
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common 
muscular dystrophies (incidence of 1:7,500 – 1:14,000), and third most common overall 
(Lunt and Harper, 1991; Orphanet, 2009), although its cause is still not clear.  The 
disease is generally late onset, producing progressive weakening of the skeletal muscles 
particularly in the face, shoulder girdle, and upper arms (Padberg, 1982; Pandya et al., 
2008).  FSHD1A (OMIM 158900), the most common form of FSHD (~98% of all cases), 
is associated with a contraction of the large D4Z4 tandem repeat array at chromosome 
4q35 from as many as 150 repeats in the unaffected population to between 1 and 11 
copies of the D4Z4 repeat unit in FSHD patients (Lunt et al., 1995; Wijmenga et al., 
1992).  Presumably, this deletion leads to epigenetic changes and subsequently 
upregulation of FSHD1A genes that ultimately leads to the pathology (de Greef et al., 
2008). Multiple candidate genes have been proposed to lead to FSHD pathology based in 
part on their position with D4Z4 repeats (Gabriels et al., 1999; Snider et al., 2009; van 
Deutekom et al., 1996; Wijmenga et al., 1993), differences in FSHD patient expression 
compared to unaffected controls (Ansseau et al., 2009; Bodega et al., 2009; Bosnakovski 
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et al., 2008; Gabellini et al., 2006; Rijkers et al., 2004; Winokur et al., 2003), and 
phenotypes when overexpressed in animal models (Gabellini et al., 2006; Hanel et al., 
2009; Liu et al.; Wuebbles et al., 2009; Wuebbles, 2010).  This study focuses on the 
FSHD candidate gene FRG1 (FSHD region gene 1), encoding a highly conserved protein 
of unknown cellular function in human muscle (Grewal et al., 1998). 
FRG1, located 125kb centromeric to the FSHD1A deletion, was one of the early 
candidate genes for FSHD (van Deutekom et al., 1996), yet expression studies have 
failed to find significant FRG1 misexpression in FSHD patient derived muscle cells and 
biopsies (Arashiro et al., 2009; Klooster et al., 2009; Masny et al.; Osborne et al., 2007).   
Furthermore, there is a lack of understanding towards FRG1’s normal cellular function.  
Studies using Xenopus as a model for vertebrate development found frg1 was widely 
expressed early and throughout development, showing elevated levels in vascular tissues 
and developing muscles (Hanel et al., 2009; Wuebbles et al., 2009).  Morphilino 
knockdown and overexpression studies show frg1 is necessary for in development of the 
musculature and vasculature (Hanel et al., 2009; Wuebbles et al., 2009).  Developmental 
analysis of the C. elegans FRG1 ortholog (FRG-1) showed a conserved expression 
profile throughout development (Liu et al.).  Much like Xenopus, increased FRG-1 levels 
in C. elegans produced developmental defects in the musculature.     
There is little known in regards to FRG1’s precise function.  Overexpression in 
cell culture originally suggested FRG1 is a nuclear/nucleolar protein (van 
Koningsbruggen et al., 2004; van Koningsbruggen et al., 2007), and has been identified 
as a component of the spliceosome (Rappsilber et al., 2002), suggesting it is involved in 
RNA biogenesis.  However, work in C. elegans show that the endogenous FRG-1 is both 
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a nuclear and cytoplasmic protein, and localized to muscle attachment sites (Liu et al.).  
Furthermore, FRG-1 has F-actin bundling activity consistent with its localization to 
muscle attachment sites (Liu et al.).  While previous studies provide potential insight into 
FRG-1’s function in human muscle development and disease, it is not known how these 
results translate to the human condition and potentially FSHD.   
We have found endogenous human FRG1 is prominently expressed in muscle and 
vasculature, the two tissues affected in FSHD.  Furthermore, we have identified three 
subcellular pools of FRG1:  in the nucleus, cytoplasm, and on sarcomere.  Interestingly, 
the distribution of FRG1 during human skeletal muscle myogenesis changes dramatically 
(Hanel et al. Differentiation, submitted).  Furthermore, we find FRG1 is associated with 
RNA and cytoplasmic localization is dependent upon the integrity of the actin 
cytoskeleton (Sun et al. manuscript in preparation).  Here we show FRG1 is a dynamic 
protein by shuttling between the nucleus and cytoplasm, suggesting that subcellular pools 
of FRG1 and its ability to bind RNA and bundle actin may be linked.   
 
RESULTS 
 
FRG1 is a nuclear-cytoplasmic shuttling protein   
The endogenous FRG1 is localized in both the nucleus and cytoplasm.  Nuclear 
shuttling assays were performed (Figure C.1) to determine if these two pools of FRG1 
were linked.  Murine C2C12 cells, easily identifiable by their DNA-dense nuclear foci, 
were transfected with a plasmid expressing epitope tagged HA-FRG1 and allowed to 
accumulate HA-FRG1 overnight.  Cycloheximide (CHX) was added to the culture media 
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to block translation and the cells were fused with non-transfected HeLa cells, readily 
identifiable by their DNA poor nucleoli, in continued presence of CHX, and HA-FRG1 
localization was monitored over time by immunocytochemistry (ICC) probing for HA.  
Thus, any HA signal in the HeLa cells represents FRG1 protein synthesized in the C2C12 
cells.  Within two hours of starting the fusion FRG1 synthesized in a C2C12 cell (Figure 
C.1A-D, white arrow) had begun to accumulate in the nuclei and concentrate the in 
nucleoli of a fused HeLa cell (Figure C.1A-D, blue arrow).  This nuclear import of FRG1 
was more evident at three hours (Figure C.1E-H) and at four hours appeared to have 
reached equilibrium (Figure C.1I-L).  As the amount of cytoplasmic HA-FRG1 is almost 
undetectable, we deduce that much of the HeLa nuclear HA-FRG1 came from the C2C12 
nuclear FRG1 and conclude that FRG1 shuttles between the nucleus and cytoplasm. 
 
FRG1 shuttling is dependent on RNA polymerase II-mediated transcription 
FRG1 has been shown to shuttle between the nucleus and cytoplasm (Figure 
C.1).  Considering FRG1’s association with RNA and interaction with TAP (Sun et al. 
manuscript in preparation), FRG1’s nuclear shuttling was investigated further.  HeLa 
cells, readily identified by Hoechst staining as containing large DNA-poor nucleoli 
(Figure C.2, blue arrows), transfected and expressing HA-FRG1 were fused with non-
transfected C2C12 cells, easily identified by the multiple DNA-bright foci (Figure C.2, 
white arrows), in the presence of translation blocking levels of cycloheximide 
(CHX).  FRG1 shuttling is illustrated by the synthesized in the HeLa cells being imported 
into the nuclei of non-transfected C2C12 cells (Figure C.2A-D).  Treatment with 
Leptomycin B (LMB) to block the CRM1/exportin1 nuclear export pathway had no 
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noticeable effect on FRG1 shuttling (Figure C.2E-H compared with C.A-D, CHX alone) 
indicating FRG1 nuclear export was through a CRM1 independent pathway.  Treatment 
with low levels of Act D such that RNA polymerase I was selectively inhibited similarly 
had no apparent effect on FRG1 shuttling or nucleolar localization (Figure C.2I-L); 
however, treatment with a higher dose of ActD to inhibit both RNA polymerase I and II 
transcription resulted in FRG1 being excluded from nucleoli and appeared consistently to 
be preferentially accumulated into the nuclei of recipient C2C12 cells (Figure C.2M-
P).  These data suggest FRG1 nuclear export is somehow linked to RNA polymerase II-
mediated transcription. 
 
DISSCUSION 
 
 Work preformed in our lab has sought to further understand the molecular 
function of FRG1 protein. It has been discovered that endogenous FRG1 is localized to 
both the nucleus and cytoplasm, and this localization changes throughout myoblast 
differentiation (Hanel et al. Differentiation, submitted). We also find FRG1 is associated 
with RNA and the cytoplasmic localization is dependent upon the integrity of the actin 
cytoskeleton (Sun et al. manuscript in preparation).  Experiments have been preformed to 
determine if the endogenous FRG1 localization to both the nucleus and cytoplasm are 
linked (Figure C.1 and C.2).  Previous cell culture studies using epitope-tagged FRG1 
transgenes characterized FRG1 as near exclusively nuclear with strong nucleolar and 
nuclear speckle concentrations implicating FRG1 in RNA biogenesis (van 
Koningsbruggen et al., 2004; van Koningsbruggen et al., 2007).  Although we do not 
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observe endogenous FRG1 strictly in the nucleus, it does accumulate in the nucleoli 
during myotube formation, and interacts with RNA, supporting a role in RNA biogenesis 
(Hanel et al. Differentiation, submitted; Sun et al. manuscript in preparation).  When 
HeLa cells are HA-FRG1 recipient cells in our nuclear shuttling assays, the transiently 
expressed FRG1 is almost exclusively in the recipient nuclei and specifically in the 
nucleoli (Figure C.1), despite the endogenous FRG1 showing both cytoplasmic and 
nuclear staining (Hanel et al. Differentiation, submitted).  Furthermore, nuclear shuttling 
appears to somehow be linked to RNA polymerase II-mediated transcription.  These data 
indicate that the majority of overexpressed FRG1 protein is nuclear and preferentially 
nucleolar.  This raises the question of how is the exogenous or overexpressed FRG1 
different from the endogenously regulated FRG1?  It is interesting to note that different 
cell types showed different ratios of nuclear to cytoplasmic FRG1 with undifferentiated 
and fully differentiated muscle cells showing the greatest amount in the cytoplasm.  Since 
exogenous or overexpressed FRG1 preferentially accumulates in the nucleus, potentially 
a certain cell-type specific level of endogenous FRG1 is capable of being actively 
maintained in the cytoplasm (FRG1 is ~29kDa) at any one time and any increases in 
FRG1 protein levels result in default FRG1 nuclear localization.  Combined with the 
dynamics shown by the nuclear shuttling assays, this would predict that eventually the 
exogenous or overexpressed FRG1 would show the similar cytoplasmic staining albeit 
with the intense nuclear staining, dependent on the turnover rate for the endogenous 
cytoplasmic retained FRG1.  This is in fact exactly what was seen in the C. elegans study 
on FRG-1; the overexpressed epitope tagged FRG-1 intensely localized to the nuclei yet 
over time, faint but detectable FRG-1 localization was seen in the body-wall muscle 
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attachment sites (Liu et al.).  We suggest that in our nuclear shuttling assays and 
published overexpression studies; the overexpressed FRG1 is actively shuttling between 
the nucleus and cytoplasm (possibly transporting RNA) but is visualized exclusively in 
the nuclei because it is not being readily retained in the cytoplasm.  Conversely, the 
endogenous FRG1 is stably maintained in the cytoplasm awaiting a signal to release it to 
the nucleus.  This cytoplasmic retention model is supported by the dramatic change in 
endogenous FRG1 localization to the nucleus in myoblasts upon stimulation of myogenic 
differentiation (Hanel et al. Differentiation, submitted).  This model further predicts that 
even small changes in FRG1 levels would alter its subcellular distribution, aberrantly 
increasing its levels in the nucleus.  Active cytoplasmic retention of FRG1 likely involves 
interaction with other proteins to anchor it.  Recently we showed that FRG1 is a bona fide 
F-actin binding and bundling protein (Liu et al.), further supporting a cytoplasmic role 
for FRG1.   
Overall, our lab has shown FRG1, a protein that is critical for muscle and vascular 
development, is a dynamic nuclear and cytoplasmic protein that can bind RNA, bundle 
actin, and localize to the sarcomeric.  Furthermore, our studies place FRG1 as the only 
current FSHD candidate gene whose product is directly linked to the skeletal muscle 
contractile apparatus.   
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MATERIALS AND METHODS 
 
Nuclear shuttling assay   
The assay was carried out essentially as described (Kawamura et al., 2002).  The 
HA-FRG1 expression plasmid was generated by subcloning the human FRG1 coding 
sequence into pcDNA3.1 HA (Matzat et al., 2008). Murine C2C12 cells (~60% 
confluent) were transfected with pcDNA3.1HA-FRG1 using TransIT-LT1 reagent (Mirus 
Bio LLC, Madison, WI) and allowed to grow for 24 hrs.  The cells were removed by 
trypsinization, washed with PBS, plated on poly-L-lysine coated coverslips (1 x 105/cm2) 
and allowed to adhere for 2 hrs before non-transfected HeLa cells were overlayed (5 x 
104/cm2) onto the transfected C2C12 cells for 3 hours.  The co-cultures were incubated 
with 100μg/ml Cycloheximide (CHX) for 15 min to stop translation, and the cells were 
fused by adding 50% (wt/vol) polyethylene glycol 4000 in DMEM for 2 min.  The 
fusions were immediately washed with DMEM and then incubated with 100μg/ml CHX 
for 2, 3, or 4 hrs followed by ICC analysis. The cells were fixed with 4% formaldehyde 
(FA) in PBS for 15 min, immunostained with HA monoclonal antibody clone 3F10 
(1:100) (Roche) as described below, and co-stained stained with Hoechst 33342 (5 μg/ml 
in PBS). 
 
ICC staining 
HeLa, C2C12, and MDSC, were fixed in 4% FA in PBS and HSMM were fixed 
in 2% FA in PBS, for 15 min at room temperature (RT). After fixation, cells were 
permeablized with 0.25% Triton-X 100 in PBS for 10 min on ice, and subsequently 
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blocked with 2% BSA in PBS for 30 min at RT. Primary antibody incubations were 
carried out at RT for 1 hr up to overnight at 4°C and secondary antibody incubations 
were for 40 min at RT. 
 
Microscopy 
Fluorescence mages were taken by fluorescence microscopy using an Olympus 
BX60 microscope equipped with a SpotRT monochrome model 2.1.1 camera and Spot 
Advanced software (Diagnostic Instruments, Sterling Heights, MI). 
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FIGURES 
 
 
 
Figure C.1: FRG1 shuttles between the nucleus and cytoplasm.  (A-L) Murine C2C12 
cells, morphologically distinguished by their DNA-bright foci (white arrow), expressing 
HA-FRG1 (red) and treated with CHX were fused with HeLa cells, distinguished by their 
DNA-poor nucleoli (blue arrows) in the presence of CHX.  (A-D) Two hours into the 
fusion process FRG1 translated in the C2C12 cells begins to localize in the HeLa cell 
nuclei (C’, longer exposure of C) and specifically the nucleoli (D, blue arrows).  This 
translocation of FRG1 from C2C12 to HeLa nuclei is more evident at 3 hours (E-H) and 
at 4 hours (I-L), appearing to have reached equilibrium between the two cell type nuclei 
(K).  Hoechst 33342 staining (green) identified nuclei. Bars = 10 μm 
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Figure C.2:  FRG1 nuclear-cytoplasmic shuttling is independent of LMB but affected by 
inhibition of RNA polymerase II-mediated transcription.  HeLa cells, distinguished by 
clear DNA-poor regions (blue arrow), expressing HA-FRG1 were fused to murine C2C12 
cells distinguished by DNA-rich foci (white arrow) in the presence of the translation 
inhibitor CHX for 3 hours with or without additional treatments described. Unfused 
C2C12 cells (examples indicated by *) do not express HA-FRG1.  (A-D) HA-FRG1 
expressed in HeLa cells localizes to C2C12 nuclei 3 hours after inducing fusion, showing 
that FRG1 shuttles between the nucleus and the cytoplasm. Additional cell fusion 
experiments were carried out in the presence of LMB (E-H), low levels of ActD (I-L) to 
shut down RNA polymerase I mediated transcription, and high levels (M-P) of ActD to 
shut down RNA polymerase I and II mediated transcription, respectively. LMB or low 
does of ActD treatment do not affect FRG1 shuttling. Under high ActD concnetrations, 
HA-FRG1 accumulated in the recipient C2C12 cells, and was excluded from the HeLa 
nucleoli. Bars = 10 µm. 
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